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7ABSTRACT
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, OMIM
240300) is a rare autosomal recessive disorder caused by mutations in the autoimmune
regulator (AIRE) gene located on chromosome 21 (21q22.3). AIRE deficiency causes a loss in
central immune tolerance, leading to the failure to eliminate autoreactive T cells in the thymus
and allowing their escape to the periphery. Because of a founder effect, APECED is
particularly prevalent in Finland (1/25,000) but is observed worldwide with variable
prevalence. APECED patients are susceptible to mucocutaneous candidiasis and multiple
endocrine autoimmune diseases such as primary hypoparathyroidism, adrenal insufficiency,
primary hypogonadism, type 1 diabetes, hypothyroidism, and hypophysitis. They may also
develop additional nonendocrine autoimmune diseases, such as alopecia areata/totalis, vitiligo,
gastro-intestinal (GI) diseases, keratitis or tubulointerstitial nephritis (TIN). In addition, the
patients typically develop a variety of serum tissue-specific autoantibodies, which are
predictive of the development of autoimmune disease and anticytokine antibodies such as
those against type I interferons and Th17-related interleukin IL-17 and IL-22.
The aim of this thesis was to study such manifestations of APECED that have not been well
characterized before and also, to study health-related quality of life among Finnish APECED
and Addison’s disease/APS2 patients.
We evaluated the clinical GI features and searched for novel markers of GI dysfunction in a
Finnish cohort of 31 APECED patients. The main upper GI symptoms were dysphagia and
retrosternal pain (45%) and the lower GI symptoms were constipation (48%), diarrhoea (45%)
and malabsorption (16%). Previously, L-amino-acid decarboxylase (AADC) and tryptophan
hydroxylase type 1 (TPH-1) antibodies have been demonstrated in APECED. AADC
antibodies were found in 51% and TPH-1 antibodies in 39% of all patients. Also,  a T cell
response to AADC was detected in 43%. One third of the patients had autoimmune
enteropathy (AIE)-related 75 kDa antigen (AIE-75, 33%) and villin (29%) autoantibodies, and
antibodies against brush borders and Paneth cells (PCs) were detected in 29% and 20%,
respectively. Mucosal intestinal IL-17 expression was decreased or negative in 77% of the
intestinal samples. Duodenal chromogranin A and serotonin expression was absent or
decreased in 50% and 66% of the patients, respectively. Of the clinical symptoms,
constipation correlated with negative serotonin staining (p < 0.05) and with
AADC antibodies (p = 0.019). Importantly, we found a correlation between autoantibodies
against AADC, which are critical for serotonin and DOPA synthesis, and constipation.
Constipation was also associated with a lack of serotonin expression in the enteroendocrine
cells (EECs). Paneth cells (PCs) were lacking in the duodenum in 20% of our intestinal
samples, even though this was not associated with GI symptoms.
In this Finnish APECED patient cohort, 17% (5/30) had moderate-to-severe renal failure,
including 10% (3/30) with TIN requiring transplantation, haemodialysis or
immunosuppressive treatment. However, the latter did not seem to be efficient in controlling
disease progression. All 3 patients with TIN had circulating antibodies against the distal part
of the nephron, as did 30% of all cohort cases.  The pathogenic relevance of such circulating
antibodies is still unclear.
The immunological basis of hypoparathyroidism in APECED was explored by studying
circulating calcium-sensing receptor (CaSR) and NALP5 antibodies. Although they were
detected in 16 of 44 (36%) and 13 of 44 (30%) patients, respectively, we failed to find any
clinically relevant statistical association.
These APECED patients did not present circulating antibodies for other autoimmune diseases
such as rheumatoid arthritis, celiac disease, bullous pemphigoid or pemphigus vulgaris. Some
patients had antinuclear antibodies at a low-titre without clinical significance.
8Secondly, we evaluated the health-related quality of life among Finnish APECED and
Addison’s disease/APS2 patients and sought to determine which factors may predict a
possible impairment.
Using health-related quality of life (HRQoL) questionnaires for APECED (SF-36) and
Addison’s disease/APS2 patients (SF-36, 15D), we indeed observed impaired HRQoL. For
the APECED patients, general health, emotional well-being and energy/vitality were the most
diminished aspects of  HRQoL.  Among the patients with Addison’s disease/APS2, compared
to a large control population, physical or emotional role functioning, energy/vitality and
general health were most affected. Discomfort and symptoms, vitality, and sexual activity
were the most affected dimensions of the 15D scores. Affiliation with a patients’ association,
female gender, the presence of non-APS2 inflammatory comorbidities, lower educational
level and a longer disease duration were independent predictors of impaired HRQoL in these
patients.
Taken together, the results of this thesis show that APECED patients are genetically prone to
develop autoantibodies to a multitude of tissue antigens but are still tolerant to some common
autoantigens. The true clinical and biological relevance of these circulating autoantibodies has
not yet been elucidated, and it is possible that they are only a reflection of T cell-mediated
immunity. They may, however, have a cumulative effect and clinical disease may arise only
in patients with a combination of circulating antibodies, as seen in diabetes type 1. This may
explain why we failed to find any association between any single type of antibody and a given
symptom. For the lower GI track manifestations, we hypothesise a cumulative effect of the
autoimmunity directed against both the enteroendocrine cells and the Paneth cells, leading to
a dysfunction in both the secretion of serotonin in the gut and the secretion of
antimicrobiobial defensins.  Such a disturbance would have an effect on the gut microbiota.
The question of whether the neutralising antibodies against cytokines may have a paradoxical
protective effect is open to debate. Lastly, despite having a high number of manifestations,
patients with APECED seem to cope with their disease. Patients with Addison’s disease have
significantly impaired HRQoL compared to the general population.
9TIIVISTELMÄ
Autoimmuunipolyendokrinopatia-kandidiaasi-ektodermidystrofia (APECED, OMIM 240300)
on harvinainen, autosomissa peittyvästi periytyvä sairaus, joka aiheutuu mutaatioista
kromosomissa 21 (21q22.3) sijaitsevassa autoimmune regulator (AIRE)  –  geenissä.  AIRE:n
toiminnallinen puutos johtaa n.s keskusimmuunitoleranssin menetykseen siten että
autoreaktiiviset T-solut eivät tuhoudu kateenkorvassa vaan pääsevät karkaamaan perifeeriseen
verenkiertoon. APECED:in esiintyvyys Suomessa on erityisen korkea (1/25,000) johtuen ns.
perustaja-mutaatiosta AIRE-geenissä, mutta tautia tavataan myös muualla maailmassa
vaihtelevalla esiintyvyydellä. APECED-potilaat ovat alttiita ihon ja limakalvojen krooniselle
hiivatulehdukselle ja heillä voi esiintyä useita autoimmuunitauteja, kuten lisäkilpirauhasen,
lisämunuaisen kuoren, kilpirauhasen sekä sukuelinten vajaatoimintaa, tyypin 1 diabetesta ja
aivolisäkkeen tulehdusta. Näiden lisäksi APECED-potilaat kärsivät usein myös muista ei-
endokriinisistä autoimmuunitaudeista kuten pälvikaljusta (alopesia), valkopälvestä (vitiligo),
silmän sarveiskalvon tulehduksesta, munuaisputkien tulehduksesta (tubulointerstitiaalinen
nefriitti, TIN),) sekä suoliston sairauksista. Potilailla havaitaan tyypillisesti seerumissa
erilaisia kudos- ja elinspesifejä autovasta-aineita sekä vasta-aineita useita
tulehdusvälittäjäaineita eli sytokiineja kohtaan.  Viime mainitut kohdistuvat tavallisimmin
tyypin I interferonia sekä Th17-immuunivasteeseen liittyviä interleukiineja IL-17 ja IL-22
kohtaan ja ennakoivat autoimmuunitaudin puhkeamista.
Tässä väitöskirjassa on tutkittu tarkemmin kahta aiemmin huonosti tunnettua APECED:iin
liittyvää oireistoa: ruoansuolatuskanavan sekä munuaisten ja virtsateiden oireita.
Kyselytutkimuksen avulla kartoitimme potilaiden kokemat ruuansulatuskanavaperäiset oireet
ja tutkimme suoliston toimintahäiriöiden tautimekanismia 31 suomalaista APECED-potilasta
käsittävässä aineistossa. Tyypillisiä ylemmän ruoansulatuskanavan oireita olivat
nielemishäiriöt ja rintalastan takainen kipu (45%) ja  alemman ruoansulatuskanavan osalta
ummetus (48%), ripuli (45%) ja imeytymishäiriöt (16%). Jo aiemmin on tiedetty APECED-
potilailla esiintyvän vasta-aineita suoliston toiminnan kannalta keskeisten
enteroendokriinisten (EE) solujen erittämiä entsyymejä  tryptofaanihydroksylaasia (TPH-1) ja
aromaattista L-aminohappodekarboksylaasia (AADC) kohtaan. Potilasaineistossamme
AADC-vasta-aineita esiintyi 51%:lla sekä TPH-1 vasta-aineita 39%:lla potilaista. Uutena
löydöksenä osoitimme T-soluperäisen immuunivasteen AADC:tä kohtaan 43%:llä.
Kolmasosalla potilaista oli osoitettavissa autovasta-aineita myös autoimmuuni enteropatiaan
liittyvää antigeenia (AIE-75) sekä ravinnon imeytymisestä vastaavien enterosyyttien
mikrovilluksissa esiintyvää villiiniä vastaan. Lisäksi löysimme vasta-aineita suolen
sukasaumaa (29% potilaista) ja suolirauhasten Panethin soluja (20% potilaista) vastaan.
Suolen limakalvon IL-17:ää tuottavien solujen määrä oli alentunut tai puuttui 77%:ssa
tapauksista. Pohjukkaissuolen kromograniini-A-proteiinia tuottavien EE- solujen määrä oli
vähentynyt tai puuttui 50%:ssa ja vastaavasti serotoniinia tuottavien solujen määrä 66%:ssa
suolistonäytteistä. Potilaiden oireista ummetus korreloi negatiivisesti EE- solujen serotoniini-
ilmentymisen (p<0.05) sekä AADC-vasta-aineiden kanssa (p<0.05). Huomionarvoista on, että
havaitsimme merkittävän yhteyden ummetuksen ja serotoniini- ja dopamiinisynteesille
keskeistä AADC-entsyymiä vastaan muodostuneiden vasta-aineiden välillä. Uusi havainto oli
myös se, että suolistoon antimikrobisia defensiinejä tuottavat Panethin solut puuttuivat
20%:ssa potilaiden duodenum-näytteistä, joskaan tämä ei suoraan korreloinut kliinisten
oireiden kanssa.
Tutkimistamme APECED- potilaista 17% (5/30) kärsi keskivaikeasta tai vaikeasta munuaisen
vajaatoiminnasta, ja 10%:lla (3/30) potilaista oli TIN, joka vaati elinsiirteen, hemodialyysiä
tai immunosuppressiivistä hoitoa. Näistä viime mainittu ei kuitenkaan osoittautunut riittäväksi
taudinkulun hallinnoimisessa. Kaikilla kolmella TIN:istä kärsivällä potilaalla todettin
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verenkierrossa vasta-aineita nefronin distaalista osaa, munuaistiehyettä kohtaan. Samoja
vasta-aineita löytyi kaikkiaan 30%:lta aineistomme potilaista, mutta niiden merkitys TIN:in
patogeneesissä on vielä tuntematon. Tutkimme myös APECED:issä esiintyvään
lisäkilpirauhasen vajaatoimintaan liittyviä immunologisia taustamekanismeja määrittämällä
verenkierrossa olevia kalsiumia tunnistavaa reseptoria (CaSR) ja NALP5-valkuaista kohtaan
muodostuneiden vasta-aineiden määrän. Huolimatta siitä, että osoitimme vasta-aineita
CaSR:ia vastaan 16/44 (36%) potilaalla ja NALP5:ttä vastaan 13/44 (30%) potilaalla, emme
löytäneet kliinisesti relevanttia korrelaatiota. APECED-potilaillamme ei ollut veressään
muussa väestössä tavallisten autoimmuunitautien kuten nivelreuman, keliakian, ihon
autoimmuuni rakkulatautien (pemfigoidi ja pemfigus) vasta-aineita, mutta joillakin heistä oli
matala-tiitterisiä tumavasta-aineita ilman niihin liittyviä kliinisiä muutoksia.
Väitöskirjaan sisältyvät myös alkuperäistutkimukset potilaiden elämänlaadun kannalta
keskeisistä tekijöistä ja terveyteen liittyvästä elämänlaadusta suomalaisilla APECED- ja
Addisonin tauti/APS2 –potilailla. Käyttäessämme terveyteen liittyviä kyselytutkimuksia (SF-
36) APECED-potilailla sekä (SF-36 sekä 15D) Addisonin tauti/APS2-potilailla, kävi ilmi, että
molempien potilasryhmien elämänlaatu oli alentunut. APECED-ryhmässä elämänlaatuun
vaikuttivat negatiivisimmin heikentyneet yleinen terveydentila, henkinen hyvinvointi sekä
energisyys/elinvoima. Addisonin tauti/APS2-potilailla elämänlaatuun negatiivisimmin
vaikuttivat alentunut yleinen fyysinen ja emotionaalinen toiminta, terveydentila sekä
energisyys/elinvoima. 15D-kyselyn merkittävimmin muuttuneita tekijöitä olivat vaivat ja
oireet, elinvoima sekä seksuaalinen aktiivisuus. Näiden potilaiden heikentyneeseen
elämänlaatuun vaikuttivat eniten seuraavat erilliset tekijät: potilasyhdistykseen kuuluminen,
naissukupuoli, muut kuin APS-2:een kuuluvat tulehdustaudit, alempi koulutustaso sekä
pitkittynyt sairauden kesto.
Tässä väitöskirjassa esitetyt tulokset osoittavat, että APECED-potilailla on runsaasti
autovasta-aineita monia kudosantigeeneja vastaan mutta samalla potilaat ovat tolerantteja
tietyille yleisille autoantigeeneille. Näiden kiertävien autovasta-aineiden lopullinen kliininen
sekä biologinen merkitys on vielä tuntematon mutta on mahdollista, että ne ovat vain yksi  T-
soluvälitteisen immuniteetin osa-alue. On mahdollista, että näillä kiertävillä vasta-aineilla on
kumulatiivinen vaikutus ja oireiden puhkeamiseen vaaditaan vasta-aineiden yhdistelmä, kuten
on esimerkiksi tyypin 1 diabeteksessä. Tämä voisi selittää myös miksi yksittäisten vasta-
aineiden ja kliinisten oireiden välillä ei tässä työssä aina voitu osoittaa merkitsevää
assosiaatiota.
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PG Parathyroid glands
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REVIEW OF THE LITERATURE
1. Autoimmune polyendocrine syndromes
Autoimmune polyendocrine syndromes (APS), sometimes called polyglandular autoimmune
syndromes in the literature, are a heterogeneous group of rare disorders characterised by
autoimmune activity against at least a minimum of 2 endocrine glands. However, the term of
‘polyendocrinopathy’ is misleading as these patients may also develop nonendocrine
autoimmune disorders (Cutolo 2014; Maréchaud 2005). The classification of APS includes 4
types (Neufeld et al 1980, Betterle et al 2003) (Figure 1). However, the 2 major APS are type
1 and type 2, each with a strong genetic component as they occur in multiple generations in
type 2 and in siblings in type 1 (Cutolo 2014). The list of polyendocrine syndromes is much
broader and includes other diseases that will not be discussed further, such as immune
dysfunction polyendocrinopathy X-linked (IPEX) (Eisenbarth et al 2004), thymoma-
associated autoimmune disease, POEMS syndrome and Wolfram syndrome (Cutolo 2014).
Briefly, APS  type  1 (APS1), or autoimmune polyendocrinopathy-candidiasis-ectodermal
dystrophy (APECED), is clinically defined by the presence of 2 of the 3 classical ‘major’
components (also known as ‘Whitaker’s triad’), i.e. autoimmune adrenocortical insufficiency
(Addison’s disease, AD), hypoparathyroidism (HP) and chronic mucocutaneous candidiasis
(CMC). If a sibling has a definite APECED, having only one of these conditions is sufficient
to make the diagnosis (Husebye et al 2009).
APS type 2 (APS2, also called Schmidt’s syndrome) is by far the most common
polyendocrine syndrome including AD (prevalence 1/20,000). It is a complex genetic disorder
with strong HLA DR3, DR4 and also B8 association. APS2 is usually diagnosed during
adulthood (20 to 40 yrs), even though children may be affected. AD is the first manifestation
in half of the cases. In 20% of the cases, T1D or thyroid autoimmune disease (autoimmune
thyroiditis, primary hypothyroidism, Grave’s disease) can be found simultaneously and, in the
remaining 30%, they can precede AD. Patients with APS2 develop autoimmunity sequentially
over a period of many years. A high number of endocrine and nonendocrine disorders can be
associated with APS2, but HP is by definition not part of APS2 (Maréchaud 2005; Cutolo
2014). The literature also mentions APS3, which involves the same endocrine disorders as in
APS2, but without adrenal failure. If the combination of autoimmune endocrine gland
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disorders does not meet the above-mentioned criteria, the disease may be categorised as APS4
(Cutolo 2014) (Figure 1).
Figure 1. Autoimmune Polyendocrine Syndromes: APS1, APS2 and IPEX
2. Autoimmune polyendocrine syndrome type 1 / Autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy
APECED (OMIM 240300) is a monogenic autosomal recessive disorder caused by mutations
in the AIRE (autoimmune regulator) gene, located on chromosome 21 (21q22.3).
2.1. Epidemiology
APECED is a rare disease that displays a worldwide distribution, as illustrated by small series
of patients collected in the USA (Wang et al 1998), India (Zaidi et al 2009), and Japan, where
the prevalence is estimated to be 1:10,000,000 (Sato et al 2002). However, APECED has been
mainly reported in Europe. Due to a founder effect, APECED is overrepresented in Finland
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with an ‘official’ prevalence of 1/25,000 (Ahonen et al 1990, Perheentupa 2006) and belongs
to the ‘Finnish Disease Heritage’ (Norio 2003, Norio 2003b). Nevertheless, it is possible that,
due to population migration, the current estimation of APECED patients is lower. However, a
higher prevalence was found among Iranian Jews in Israel (1/9000) (Zlotogora et al 1992).
Although APECED is very rare in Italy, 3 hot spots have been identified: Sardinia (1/14,400)
(Rosatelli et al 1998), Apulia (Betterle et al 2012) and Venetia (Cervato et al 2009). In the
northwestern part of France, it was estimated to affect 1/500,000 inhabitants (Proust-Lemoine
et al 2010, Proust-Lemoine et al 2012). The prevalence in various Eurasian countries with the
main AIRE mutations is summarised in Figure 2.
Figure 2. Prevalence of APECED and the main AIRE mutations in Europe and Israel
2.2. Clinical manifestations
APECED predisposes to mucocutaneous candidiasis, multiple endocrine autoimmune diseases,
nonendocrine autoimmune disorders and ectodermic anomalies (Husebye et al 2009, Proust-
Lemoine  et  al  2012).  Apart  from  the  3  ‘major’  components  (CMC,  HP  and  AD),  there  are
additional so-called ‘minor’ components that include the aforementioned autoimmunity and
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ectodermal anomalies (Figure  3). There is an extreme variability in the number of clinical
manifestations, ranging from 1 to 10 (Perheentupa 2006).
APECED manifests mainly during early childhood or adolescence, with a progressive
manifestation of various disorders, even though rare cases have been reported during early
adulthood between 18 and 28 years of age (Magitta et al 2008). The female-to-male sex ratio
varies according to series, from 0.3 to 2.5. The triad is usually complete after the second
decade, but it can remain incomplete. The absence of previous family history, the phenotypic
variability of APECED, added to a possible lack of knowledge of the disease by the
physicians, may lead to mis- or underdiagnosis (Husebye et al 2009). Table 1 summarises the
clinical data of approximately 20 published series. The tissue-specific autoantibodies (Abs)
are summarised in Table 2.
Figure 3. Tissues affected by APECED (to the exclusion of candidiasis) (modified from
Linx2Learn, http://www.webset-lms.com/vtct/Course.aspx?id=5221, with authorization of
VCTC)
2.2.1. Chronic mucocutaneous candidiasis
CMC may occur in patients with primary immunodeficiencies and various other pathological
conditions, such as severe combined immunodeficiency, combined immunodeficiency-like
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dedicator of cytokinesis 8 deficiency, signal transducer and activator of transcription (STAT)
3 deficiency causing autosomal-dominant hyper-IgE syndrome (AD-HIES), autosomal
recessive (AR) IL-12Rβ1 and IL-12p40 deficiencies, AR tyrosine kinase (TYK) 2 deficiency,
and AR caspase recruitment domain nine deficiency. APECED belongs to this list of
conditions (Eyerich et al 2010, Soltész et al 2013). Candidiasis is usually the first
nonendocrine manifestation of APECED, but can appear much later after the endocrine
manifestations (Ahonen et al 1990). On the other hand, it can also be the first manifestation
and should therefore raise the suspicion of this diagnosis (Collins et al 2006).
The  prevalence  and  severity  of  CMC  during  APECED  are  variable,  according  to  the  series
(Table 1), which most likely is the result of different mutations of the AIRE gene (Kisand et
al 2011).
In the large Finnish (Ahonen et al 1990) and Italian (Meloni et al 2012) series, CMC appears
as early as the first year of life. In Sardinia, it is the first sign of APECED in 86% of the cases,
at a median age of 3 years (Meloni et al 2012). In Finland, 26% of the patients have CMC at
the age of 1, 55% at the age of 5, and after the second decade, almost all patients have CMC
(Ahonen et al 1990). It more rarely develops during adulthood (Meloni et al 2012). The
candidal infection affects the nails and the oral, vaginal, and oesophageal mucosa (Husebye et
al 2009) (Figure 4).
Oral mucous membranes are almost always affected and the clinical presentation does not
differ from regular candidiasis. Lesions are often painful and consumption of acidic or spicy
food may be impossible (Collins et al 2006, Husebye et al 2009).
Candidiasis oesophagitis affects approximately 15 to 22% of the patients (Perheentupa 2006,
Collins et al 2006), causing pain while swallowing, retrosternal pain and dysphagia (Ahonen
et al 1990, Perheentupa 2006). These manifestations are not always simultaneously associated
with oral candidiasis (Perhentupa 2006). Chronic inflammation may lead to oesophageal
stricture (Ahonen et al 1990, Betterle et al 1998, Perheentupa 2006), which needs treatment
with balloon dilatation or stenting.
Oral (tongue, gingiva, buccal mucosa) and oesophageal squamous cell carcinomas may
develop  as  a  long-term  complication  of  chronic  inflammation  mediated  by  CMC.  They  are
currently the most common malignancies associated with APECED. They result from an
inadequately treated refractory oral candidiasis, usually due to antifungal resistance.  Uittamo
et al showed that C. albicans isolated from APECED patients produced potentially mutagenic
amounts of acetaldehyde when incubated with glucose (Uittamo et al 2009).  Metastasis and
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premature death have been reported among patients older than 25 years (Rautamaa et al 2007).
Alcohol intake, active smoking, poor oral hygiene, or even the consumption of sweet products,
leading to higher acetaldehyde levels (Uittamo et al 2009), as well as immunosuppressive
therapies, are risk factors that may promote carcinogenesis for both oesophageal and oral
mucosa (Rautemaa et al 2007, Rosa et al 2008). Long-term follow-up is mandatory as
recurrences have been observed with the development of multiple carcinomas (Böckle et al
2010, Shepard et al 2012).
Oesophageal cancers during CMC unrelated to APECED have been reported (Rosa et al 2008,
Koch et al 2009), supporting the notion that chronic candidiasis plays a role in carcinogenesis
rather than APECED itself. Achalasia was reported in a patient with candidal oesphagitis who
developed subsequent oesophageal carcinoma. It remains open to debate whether achalasia
was an additional factor contributing to the carcinogenicity in this case (McCormack et al
2012).
Management of APECED patients includes ensuring excellent oral hygiene with careful and
regular dental follow-up. Dental plaque and sources of yeast in the oral cavity should be
actively  treated  (Rautemaa  et  al  2007).  Patients  should  be  advised  to  avoid  smoking  and  an
excess of alcohol. Candidiasis should be treated aggressively and regular prophylaxis should
be given. Azoles, fluconazole especially, are often recommended as first-line treatment but
this leads to the selection of resistant strains (Eyerich et al 2010). Therefore, regular fungal
sensitivity tests should be performed.  Preferably, topical polyenes (amphotericin B) should
be chosen as they are less prone to selecting resistant Candida stains (Rautemaa et  al  2007).
Echinocandins are available as an intravenous infusion, and systemic polyene (amphoptericin
B) should be restricted to systemic candidiasis (Eyerich et al 2010). Any suspicious lesions,
any erosion or ulceration that does not heal within 2 weeks (Shepard et al 2012), or any
thickening should be biopsied. Mucosal dysplasia should be surgically removed to prevent
rapid progression to carcinoma (Shepard et al 2012). In addition, any difficulties in
swallowing or eating or retrosternal pain should prompt oesophageal endoscopy (Rautemaa et
al 2007).
Cutaneous candidiasis is rather uncommon (9% of the patients) and affects only the hands and
face (Ahonen et al 1990). Destructive candidal onychomycosis and chronic paronychia affect
the fingernails more often than the toenails. (Collins et al 2006).
Vaginal candidiasis causes a discharge, pruritus and disturbance in the sex life of patients.
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The disease is chronic, but often mild with varying intervals of spontaneous regression
(Ahonen et al 1990). The incidence of candidiasis diminishes with age.
Of note, APECED patients show immunodeficiency only against Candida  and not against
other fungi or bacteria. Systemic dissemination with potential lethal evolution is possible but
quite rare and mostly due to additional iatrogenic factors such as immunosuppressive
therapies (Betterle et al 1998).
Figure 4. Big toe nail dystrophy in a Finnish APECED patient possibly related to candidiasis
21
Table 1. Percentage frequency of major and minor clinical features in APECED in different populations
USA,
Neufeld
et al,
1981
Finland,
Ahonen et
al,  1990
Finland,
Perhentupa,
2006*
Iran,
Zoglotora
et al,
1992
USA,
Wang et
al,
1998
Italy,
Perniola
et al, 2000
Italy,
Sardinia
Meloni et
al, 2012
North
Italy
Betterle,
2002**
Norway
Myhre et
al, 2001
Slovenia***,
Podkrajsek
et al,
2008
Slovenia,
Podkrajsek
et al, 2005
n 71 68 91 23 20 11 22 47 20 11 12
sex ratio M:F 0.6 nd 45:46; 0.98 11:12;0.92 8:12; 0.6 nd 9:13; 0.7 11:9;1.2 6:5;1.2 9:3; 3
Candidiasis 73 100 98 18 80 100 95 83 85 91 100
Hypoparathyroidism 76 79 85 96 100 100 77 89 85 72 83
Addison’s disease 100 72 78 22 95 82 68 77 80 91 58
Hypothyroidism 11 4 14 4 25 36 0 11 10 27 25
Diabetes type 1 4 nd 13 4 nd 0 5 4 0 nd 8
Hypogonadism 17 nd nd 38 20 18 nd 40 31 nd 8
Hypogonadism
(men)
Nd 14 12 35 nd nd nd nd nd nd nd
Hypogonadism
(women)
Nd 60 60 38 nd nd 61 nd nd nd nd
Growth hormone
deficiency
Nd nd 5 nd nd nd 23 nd nd nd nd
Pernicious anaemia 13 13 20 9 nd 9 18 15 0 9 nd
Gastritis Nd nd nd nd nd nd 32 nd 0 nd nd
Malabsorption 22 18 21-22 nd 5 18 11 10 27 25
Keratitis Nd 35 22 0 nd nd 36 6 10 nd 16
Autoimmune
hepatitis
13 12 18 nd 25 27 27 19 5 9 8
Tubulonephritis Nd nd 9 nd nd nd nd nd nd nd nd
Alopecia 32 29 39 13 40 nd 13 36 40 27 33
Vitiligo 8 13 27 nd 10 0 9 15 25 9 8
Dental enamel defect Nd 77 nd nd nd nd 72 nd 40 27 42
Cancer 1 nd 11 nd nd nd nd 7 nd nd nd
Asplenia Nd nd 9 nd nd nd 4 nd nd nd nd
*Prevalence at the age of 30 yo, ** data as given in Betterle et al 2003 *** patients from Dutch (n = 3), Serbian (n = 7) and Slovenian origin (n = 1)
nd: not determined
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Table 1. Continued
Ireland,
Collins
et al,
2006
Poland,
Stolarski
et al, 2006
Slovakia,
Magitta et al,
2008
Italy,
Mazza
et al,
2011
France,
Proust-
Lemoine et
al, 2010
Russia,
Orlova et
al, 2009
Norway,
Wolff et
al,
2007
Italy,
Betterle et
al, 1998
Italy,
Cervatto
et al,
2009
n 18 14 4 24 19 46 36*** 41 24
sex ratio M:F 7:11;0.6 5:9; 0.5 2:2; 1 nd 12:7;1.7 14:32; 2.3 20:16;1.2 0.4 Nd
Candidiasis 100 92 0 75 89 70 79 83 92
Hypoparathyroidism 77 100 50 83 63 83 82 93 96
Addison’s disease 72 50 100** 63 79 54 68 73 92
Hypothyroidism 0 0 50 25 5 20*** 12 10 21
Diabetes type 1 11 0 nd 8 5 11 9 2 8
Hypogonadism 11 14 50 13 nd nd nd nd Nd
Hypogonadism (men) nd nd nd nd 0 nd nd nd 8
Hypogonadism
(women)
nd nd nd nd 71 7 53 43 63
Hypophysitis/Growth
hormone deficiency
5 7 nd nd 5 nd 0 7 Nd
Pernicious anaemia 11 7 nd nd 21 13 nd 15 33
Gastritis nd nd nd 13 nd nd nd nd Nd
Malabsorption nd 14 nd nd 26 18 9 15 21
Keratoconjunctivitis 11 21 nd 13 37 7 8 12 Nd
Autoimmune hepatitis 16 36 nd 24 11 11 3 20 17
Tubulonephritis/renal
failure/nephrocalcinosis
nd nd nd nd nd 2 3 nd 4
Alopecia 33 21 25 25 53 27 38 37 50
Vitiligo 11 0 nd 25 21 9 20 15 33
Hyperthyroidism 5 0 nd nd nd 20*** nd nd Nd
Dental enamel defects 27 nd 25 nd 37 nd 38 nd Nd
Cancer nd nd nd nd nd nd 3 nd 16
Asplenia nd nd nd nd nd 2 nd nd Nd
**Patients recruited among 126 patients with Addison’s disease ***article mentions 36 patients but no data are provided for 2 siblings who died in childhood
nd: not determined
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2.2.2 Endocrine manifestations
2.2.2.1. Hypoparathyroidism
Primary hypoparathyroidism (HP) is the most common endocrine manifestation of APECED
in almost all patient series (Table 1), affecting 75 to 100% of the patients. Lower prevalences
are nevertheless found in France (63%) (Proust-Lemoine et al 2010). HP is the first endocrine
manifestation in 64% of the Finnish patients (Perhentupa 2006), occurring generally before
the age of 10, but it can be diagnosed also during adulthood up to 40 years of age (Gylling et
al 2003). It may also remain as the only endocrine manifestations in some patients (Ahonen et
al 1990, Zlotogora et al 1992). Interestingly, there is a distinct difference in prevalence
between the sexes, as HP occurs in 98% of the women and 71% of the men.
The clinical manifestations of HP include paraesthesia of the face and fingers, muscle cramps,
clumsiness, even seizure in the case of frank hypocalcaemia (Husebye et al 2009). Diarrhoea
and malabsorption are also symptoms of HP (Ebert 2010). More rarely, serum hypocalcaemia
can lead to electrocardiographic anomalies such as prolonged QTc intervals (Meyer et al 2007,
Buber et al 2008). Lastly, brain calcifications located in the cerebellum, basal ganglia,
thalamus, and the white matter, associated with neurological complaints such as Parkinsonism,
have been reported (Abraham et al 2010; Buber et al 2008). Diagnosis is made upon routine
laboratory findings: hypocalcaemia, hyperphosphataemia, and possible hypomagnesaemia, in
the absence of renal failure and normal or low parathormone (PTH) levels. AIRE mutations do
not differ between patients with and without HP, nor does HLA class II haplotype (Gylling et
al 2003). However, it was noted among Finnish patients that a lower and later incidence of HP
is observed in male patients, probably in relationship with AD as the manifestation in these
patients. The authors speculated that corticosteroid substitution for AD might protect against
the autoimmune process (Gylling et al 2003, Magitta et al 2008). However, this hypothesis
seems unlikely as they receive hydrocortisone only at a substitutive dosage and not at an
antiinflammatory dosage.
Several studies have tried to identify potential targets in the parathyroid glands that could
explain the occurrence of HP (Table 2). Autoantibodies (Abs) against parathyroid gland (PG)
epithelial cells have been found in 19% of the APECED patients, but at low titres and with no
difference between patients with and without HP (Gylling et al 2003). Similarly, Abs against
hyperplastic PG (37%) and PTH (3%) were ruled out as a possible explanation (Gylling et al
2003). The calcium-sensing receptor (CaSR), a pivotal receptor involved in calcium
metabolism homeostasis by sensing serum calcium levels and regulating PTH levels, has been
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suspected to be a key target of autoimmunity (Li et al 1996). However, the results have been
rather conflicting: Söderbergh et al did not find CaSR Abs in any of their 90 patients
(Söderbergh et al 2004), whereas Gylling et al found that 12% of the patients had Abs against
CaSR, but with no difference compared with control patients (Gylling et al 2003). Others
reported that CaSR Abs were present at a higher incidence among APECED patients, from
35% (Li et al 1996) to 86% (Gavalas et al 2007). It is still unclear whether or not CaSR Abs
are a specific or sensitive marker for APECED-associated HP. More recently, Abs against
NALP5 (NACHT leucine-rich-repeat protein 5), a protein selectively expressed in the
cytoplasm of chief cells in the parathyroid gland, also in testis,  breast,  and ovaries,  has been
associated with clinical and biochemical manifestations of HP during APECED. They may
have a specificity of 100% and sensitivity of 49% for the diagnosis of HP (Alimohammadi et
al 2008, Tomar et al 2012).
Idiopathic HP is quite exceptional in the general population, so APECED should be
considered  systematically  in  cases  of  HP.  During  the  follow-up  of  patients  without  HP,
plasma calcium and phosphate should be monitored once a year. The mainstay of therapy
includes vitamin D derivatives, oral calcium and magnesium supplementation. Regular
monitoring of plasma calcium at least every 2 months along with a control of plasma
magnesium, phosphate and 24h urinary calcium every 4-6 months is recommended (Husebye
et al 2009).
2.2.2.2. Addison’s disease
Except  for  Iranian  Jews,  AD affects  between 50  to  100% of  the  APECED patients.  It  is  the
result of an autoimmune adrenalitis for which the symptoms appear when 90% of the adrenal
cortex has been destroyed (Napier et al 2012). Overall, APECED accounts for 5 to 10% of all
cases of AD, but AD occurrence in children should raise the suspicion of possible APECED.
Indeed, the age of onset is usually in childhood, before the age of 15 years. It may be the first
endocrine  manifestation  in  30%  of  the  cases  before  HP,  but  it  is  seldom  the  very  first
manifestation of APECED (Perheentupa 2006). AD usually manifests with both
glucocorticoid and mineralocorticoid deficiency, but one or the other can precede (Napier et
al 2012).
The symptoms are usually fatigue, nausea, anorexia, salt craving, hypotension, weight loss,
and pigmentation of the whole skin, skin folds and gingiva. Hypotension, hyponatraemia and
hyperkalaemia are signs of mineralocorticoid deficiency while hyponatremia, hypoglycaemia,
and more rarely, anaemia, lymphocytosis, and eosinophilia disclose glucocorticoid deficiency.
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Adrenal crisis, which is usually triggered by a physical stress such as infection or surgery, is
potentially lethal in the case of lack of or delayed diagnosis with vomiting, abdominal pain,
and hypotension up to hypovolemic shock (Napier et al 2012). Adrenal glucocorticoid
deficiency is detected by a Synacthen test. In evolved stages, basal serum cortisol is low and
adrenocorticotropic hormone (ACTH) levels are elevated. Minerolocorticoid deficiency is
diagnosed by low aldosterone levels and elevated plasma renin activities (Husebye et al 2009).
Abs against 21-hydroxylase (21-OH) are found and confirm the autoimmune origin of the
disease. Patients with 21-OH Abs may develop AD over time. In APECED, 2 other adrenal
targets are considered as markers of AD: side-chain cleavage enzyme (SCC) and 17alpha-
hydroxylase (17a-OH) (Table 2). Abs against at least one of the 3 aforementioned antigens is
found in 84% of the patients with AD (Söderbergh et al 2004), but the detection of 21-OH and
SCC is enough to suspect AD (Söderbergh et al 2004).
Replacement therapy is similar to that for patients with isolated AD, with oral hydrocortisone
with or without a fludrocortisone regimen (Husebye et al 2009, Napier et al 2012).
2.2.2.3. Gonadal insufficiency
Primary hypogonadism affects females more often than males, mainly during the second
decade (Proust-Lemoine et al 2012). Ovarian insufficiency (or premature ovarian failure) may
occur at an early age, in the adolescent or adult years, resulting in the development of primary
amenorrhoea,  lack  of  puberty  or  delayed  or  arrested  puberty  and  premature  menopause.  By
the age of 30 years, 60% of the women have ovarian failure. Oestrogen levels are low while
gonadotropins (follicle-stimulating hormone and luteinizing hormone) are elevated
(Dragojević-Dikić et al 2010). Oestrogen replacement is started at pubertal onset to maintain
normal feminine development. In the case where Abs are detected, pregnancy should not be
delayed. Cryoconservation of oocytes and embryo donation are possible (Husebye et al 2009)
and available in Finland.
Testicular insufficiency is  rarer  among  males  as  it  affects  only  from  12  to  35%  of  the
APECED patients (Ahonen et al 1990, Zlotogora et al 1992). However, the causes are diverse:
azoospermia, primary testicular atrophy, or LH and FSH deficiency. AD is often associated.
However, in some cases, the cause can be unrelated to APECED (mumps, orchitis, etc.)
(Perheentupa 2006).
Abs against SCC were found to be significantly associated with hypogonadism (79% of the
patients) (Söderbergh et al 2004) and they can be detected before any manifestations. The role
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of 17a-OH Abs is less clear (Söderbergh et al 2004). NALP5 Abs, which are already possibly
involved in HP in a context of APECED, were also found to be significantly associated with
ovarian insufficiency during APECED (Alimohammadi et al 2008). NALP5 is indeed not
only  expressed  in  the  PG  but  also  in  the  ovaries.  Almost  70%  of  the  patients  with
hypogonadism disclose significant NALP5 Abs titres. However, these Abs are neither specific
nor sensitive, as 30% of the patients without hypogonadism have those (Alimohammadi et al
2008). Of note, there are several other Abs against ovarian targets potentially involved in
immune aggression, such as gonadotropin receptor autoantigens, 3β-hydroxysteroid
dehydrogenase Abs, gonadotropin receptors Abs, zona pellucida Abs, and anti-oocyte
cytoplasm Abs against MATER (‘maternal antigen that embryos require’) (Dragojević-Dikić
et al 2010). To our knowledge, none of these have been studied in APECED women with
ovarian failure.
2.2.2.4 Thyroid autoimmunity
Thyroid involvement is reported in 0 to 50% of the cases (Table 1). It is infrequently the first
manifestation and occurs mainly during adulthood (mean age 26.5 yrs) (Perheentupa 2006).
The clinical presentation and pathology are similar to APECED-non-related hypothyroidism.
The latter can be brutal, with inflammation, thyroid gland enlargement and high titres of Abs,
or slowly progressive with a slightly altered thyroid gland. Abs against thyroglobulin,
microsomes and thyroid peroxidase are found in patients with hypothyroidism. The Abs
against thyroid peroxidase are the most sensitive and specific and should be used in clinical
practice. Some patients with normal thyroid function may disclose circulating Abs (Perniola
et al 2008) as an indication of autoimmune thyroiditis. Hyperthyroidism (Graves’s disease) is
not a feature of APECED and very few cases have been reported. However, a transient
thyrotoxicosis can occur as the first manifestation of thyroiditis before shifting to
hypothyroidism (Perheentupa 2006). This is due to the transient leakage of thyroid hormones
to the periphery because of the inflammation.
As the occurrence of thyroid dysfunction is unpredictable, patients should be monitored
regularly for TSH levels.
2.2.2.5. Type 1 diabetes
T1D  is  a  rare  feature  of  APECED,  reported  in  2  to  13%  in  the  cohorts.  In  Finland,  the
prevalence seems a bit higher, as stressed by 2 publications: 17% among a cohort of 47
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Finnish patients (Tuomi et al 1996) and 18% of 68 Finns (Gylling et al 2000). T1D results
from the destruction of pancreatic insulin-producing b-cells. It is characterised by insulitis,
islet cell Abs, b-cell-specific  T  lymphocytes  and  a  restricted  set  of  class  II  major
histocompatibility alleles. In addition, environmental factors may be involved (Boitard 2012).
In APECED, T1D develops late, usually around 30 to 40 years of age (Perheentupa 2006).
Patients  with  T1D  present  Abs  against  islet  cell  Ab  (ICA),  anti-islet  antigen  2,  a  tyrosin
phosphatase-like transmembrane protein (IA2), glutamate decarboxylase (GAD), and insulin
(IAA) (Van den Driessche et al 2009, Boitard 2012). The detection of Abs remains the only
diagnostic marker for autoimmunity in T1D in clinical practice (Boitard 2012). The more Abs,
the more at risk a normoglycaemic patient is to develop T1D within the next few years (Van
den Driessche et al 2009). Having more than 2 circulating Abs is highly predictive of
development  of  T1D while  one  or  2  is  less  predictive.  However,  the  detection  of  these  Abs
does not predict the onset of the disease in a normoglycaemic individual (Boitard 2012).
Overall, numerous pancreatic autoantigens have been identified as being recognised by T cells
in  T1D  patients:  as  mentioned  above, b-cell antigens (insulin, zinc transporter 8),
neuroendocrine antigens (GAD-65, GAD-67, IA-2), ubiquitous HSP-60 and -70 or CD38.
Evidence of the involvement of autoantigens like chromogranin or IGRP in human T1D is
lacking (Boitard 2012).
In a series of 90 Scandinavian APECED patients, Söderbergh et al found a prevalence of
positivity of 37% and 7% for GAD-65 and IA-2, respectively (Söderbergh et al 2004). Only
IA-2 was associated with T1D, with a specificity of 87% but a low sensitivity of 33%. In
previous studies, Gylling et al also showed that IA-2 and/or IAA have low sensitivity (36%)
but high specificity (96 or 100%) with a positive predictive value of 67% for T1D.
Approximately 75% of the patients with T1D have GAD-65 Abs (Tuomi et al 1996, Gylling
et al 2000), but a third of the patients without T1D also present such Abs (Tuomi et al 1996,
Gylling et al 2000) (Table 2).
To conclude, the risk of T1D increases with the number of Abs (Gylling et al 2000). The
detection of only GAD65 Abs does not invariably lead to clinical diabetes (Tuomi et al 1996).
IA-2 Abs do not predict a rapid onset as APECED patients may have circulating Abs for
several years before any functional signs of diabetes. No specific HLA haplotypes were found
to confer either susceptibility or protection from T1D (Tuomi et al 1996, Gylling et al 2000).
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2.2.2.6. Pituitary failure
Autoimmune hypophysitis leading to hypopituitarism is a rare manifestation of APECED,
being diagnosed between the ages of 5 and 15 years. The main manifestation is growth
hormone  deficiency,  reported  in  5  to  7%  of  the  cases.  Only  Meloni  et  al  reported  a  higher
prevalence  in  their  series  (23%  of  the  cases)  (Meloni  et  al  2012)  (Table  1). Other
manifestations such as hypogonadotropic hypogonadism (Ahonen et al 1990), corticotropic
hormone deficiency (Castells et al 1971) and diabetes insipidus have been reported in
anecdotal cases (Hung et al 1984; Scherbaum et 1986). Multiple central deficiencies are also
possible (Arvanitakis et al 1973).
O’Dwyer et al found that 58% (39/67) of Finnish APECED patients disclosed Abs against 49
kDa pituitary enolase (O’Dwyer et al 2007). Eighteen patients displayed reactivity against
more than one pituitary cytosolic autoantigen (105 kDa pituitary cytosolic protein n = 2, 60
kDa  pituitary  cytosolic  protein  n  =  8,  40  kDa  n  =  10,  45  kDa  n  =  11).  As  the  authors  had
patient sera obtained over 2 to 25 years, they could show a seroconversion during life and the
stability of the Abs after.  However, the presence of such Abs was not related to clinical
hypopituitarism. The question of whether such Abs are pathogenic, a simple epiphenomenon
or the possible consequence of molecular mimicry and cross-reaction with other Abs such as
candidal enolase remains open (O’Dwyer et al 2007).
In a series of 86 patients, Bensing et al found that 49% (48/86) of the patients had Abs against
TDRD6 (tudor domain-containing protein 6),  a protein mainly expressed in the testis but also
at low level in various endocrine glands, including the pituitary glands (Bensing et al 2007).
Only 6 patients in this series had GH deficiency (7%) (Bensing et al 2007). However, this Ab
was not statistically associated with any APECED manifestation. Bellastella et al (2010)
showed that there is no relationship between antipituitary Abs in the serum and anterior
pituitary dysfunction. Among the patients who had circulating pituitary Abs, only those with
positive immunostaining of only a portion of the pituitary cells and at high titres developed
clinical hypopituitarism (Bellastella et al 2010). But their series of patients with
hypopituitarism in the context of polyendocrine syndromes concerned only patients with
either APS-3 or -4 and no APECED.
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Table 2. Known tissue-specific antigen targets and autoantibodies in APECED
Disease Tissue affected Antigenic target Antigen role Prevalence in APECED Prevalence in patients
with the disease
component during
APECED
Prevalence in controls
without APECED
Adrenocortical failure Adrenal glands 21-hydroxylase (21-OH)
side-chain cleavage
enzyme (SCC)
17-a hydroxylase
Steroidogenic enzymes in
the adrenal cortex
66% (Söderbergh et al
2004)
52%  (Söderbergh et al
2004)
44%  (Söderbergh et al
2004)
75%   (Söderbergh et al
2004)
61%   (Söderbergh et al
2004)
52%   (Söderbergh et al
2004)
Hypoparathyroidism Parathyroid PG
PTH
CaSR
NALP5
Parathyroid gland
Parathormone
Extracellular domain of
the calcium-sensing
receptor on parathyroid
cells
NACHT leucine-rich-
repeat protein 5
19% (Gylling et al 2003)
3% (Gylling et al 2003)
0% (Söderbergh et al
2004) – 12% (Gylling et al
2003)
41% (Alimohammadi  et
al 2008)
19% (Gylling et al 2003)
0% (Söderbergh et al
2004) – 12% (Gylling et al
2003)
49% (Alimohammadi  et
al 2008)
0% (Gylling et al 2003)
3% (Gylling et al 2003)
3-4% (Gylling et al 2003)
0% (Alimohammadi  et al
2008)
Hypogonadism Ovaries and testis Side-chain cleavage
enzyme (SCC)
17-a hydroxylase
NALP5
Steroidogenic enzymes in
the gonads
NACHT leucine-rich-
repeat protein 5
52% (Söderbergh et al
2004)
44% (Söderbergh et al
2004)
41% (Alimohammadi  et
al 2008)
79% (Söderbergh et al
2004)
57% (Söderbergh et al
2004)
68% (Alimohammadi  et
al 2008)
0% (Alimohammadi  et al
2008)
Type 1 diabetes Endocrine pancreas GAD-65
ICA
IA2
Glutamate decarboxylase
Islet cells antibodies
Tyrosine phosphatase-like
transmembrane protein
37% (Söderbergh et al
2004) - 43% (Gylling et al
2000)
34% (Gylling et al 2000)
7% (Söderbergh et al
2004) - 10% (Gylling
2000 et al)
72.7% (Gylling et al 2000)
54% (Gylling et al 2000)
33% (Söderbergh et al
2004) - 36% (Gylling et al
2000)
nd
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Insulin Insulin 6% (Gylling et al 2000) 34% (Gylling et al 2000)
Hypothyroidism Thyroid TPO
Tg
Thyroid peroxidase
Thyroglobulin
nd
nd
nd
nd
nd
nd
Pulmonary disease Lung KCNRG (terminal
bronchioles)
Potassium channel
regulator
8% (Alimohammadi et al
2009)
88% (Alimohammadi et al
2009)
nd**
Atrophic gastritis Gastric mucosa Parietal cell
Intrinsic factor
Sodium-potassium
channel molecule of the
parietal cells
Fixation of B12 vitamin
nd
nd
nd
nd
nd
nd
Gastrointestinal
dysfunction
Gastrointestinal tract TPH-1
Histidine decarboxylase
Tryptophan hydroxylase
Pyridoxal phosphate-
dependent enzyme
47% (Ekwall et al 1998)
61% (Dal Pra et al 2004)
37% (Sköldberg et al
2003)
89% (Ekwall et al 1998)
92% (Scarpa et al 2013)
58% (Sköldberg et al
20003)
0% (Ekwall et al 1998,
Dal Pra 2004)
Autoimmune hepatitis Liver Aromatic L-amino acid
decarboxylase (AADC)
TPH
KCNRG (terminal
bronchioles)
ANA
SMA
SLA/LP
LKM1
CYP1A1
CYP1A2
DOPA  and  5-HT  to
dopamine and serotonin
Tryptophan hydroxylase
Antinuclear antibodies
Smooth muscle antibodies
Soluble liver
Antigen/liver pancreas
antigen
Liver kidney microsome 1
Cytochromes expressed
mainly in the liver
51%  (Husebye et al 1997,
Söderbergh et al 2004)
-52% (Dal Pra et al 2004)
45% (Söderbergh et al
2004)-61% (Dal Pra et al
2004)
7.9% (Alimohammadi et
al 2009)
nd
nd
0%
8% (Obermayer-Straub et
al 2001)
nd
6% (Obermayer-Straub et
92% (Söderbergh et al
2004)
92% (Söderbergh et al
2004)
23% (Alimohammadi et al
2009)
12.5% (Obermayer-Straub
et al 2001)
0%
0%
50% (Obermayer-Straub
et al 2001)– 75% (Betterle
et al 1998)
nd
35% (Söderbergh et al
nd
5.9-9% (Obermayer-
Straub et al 2001)
6-10%
0%
nd
0%
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CYP2A6
CYP2B6
Histidine decarboxylase Pyridoxal phosphate-
dependent enzyme
al 2001)-8% (Söderberg et
al 2004)
15.6% (Obermayer-Straub
et al 2001)
nd
69% (Sköldberg et al
2003)
2004)-50% (Obermayer-
Straub et al 2001)
37.5% (Obermayer-Straub
et al 2001)
nd
37% (Sköldberg et al
2003)
0%
nd
nd
Vitiligo Skin (melanocytes) Aromatic L-amino acid
Decarboxylase (AADC)
Tyrosine hydroxylase
(melanocytes)
SOX9 (cross- reaction
with SOX10
autoantibodies)
SOX10 (melanocytes)
Serotonin and dopamine
Conversion of tyrosine to
L-dopa
Transcription factors,
embryonic development of
various organs
51% (Husebye et al 1997)
-52% (Dal Pra et al 2004 )
44% (Hedstrand et al
2000)
15% (Hedstrand et al
2001)
22%
80%
nd
57% (Hedstrand et al
2000)
47% (Hedstrand et al
2001)
63%
nd
0/8 (Dal Pra et al 2004)
nd (Hedstrand et al 2000)
23% (Kemp et al 2011)*
1%  (Hedstrand et 2001)
3% (Hedstrand et al 2001)
Alopecia areata Hair follicle Tyrosine hydroxylase
(keratinocyte)
Conversion of tyrosine to
L-dopa
44% (Hedstand et al 2000) 62% (Hedstand et al 2000) 0% (Hedstand et al 2000)
19% (Kemp et al 2011)*
Hypopituitarism Pituitary gland 49 kDa enolase
40 kDa
45 kDa
60 kDa
105 kDa
58%
15%
16%
12%
3%
70% in lymphocytis
hypophysitis (Crock et al
1998)
*significant only in the alopecia universalis subgroup compared with controls
** nd in patients with autoimmune bronchiolitis
nd: not determined clearly as mentioned in the article
32
2.2.3. Nonendocrine manifestations
2.2.3.1. Alopecia areata
Alopecia areata (AA) is an autoimmune disease characterised as asymptomatic, well-defined
patches of non-scarring hair loss with no epidermal changes. It affects both males and females
and occurs in 0.1 to 0.2% of the general population (Alkhalifah et al 2010). AA mainly affects
the scalp in 90% of the cases, but can occur on virtually any hair-bearing area. The alopecia is
defined as patchy, totalis (loss of 100% of scalp hair) or universalis (loss of all scalp and body
hair) (Alkhalifah et al 2010). Nail involvement is observed in up to 66% of the patients,
mainly nail pitting, but other anomalies have been described. The nail abnormalities can occur
before, during or after the hair loss and can be associated with more extensive hair loss. In the
active phase, the histopathology of the AA area shows a peribulbar lymphocytic infiltrate on
anagen follicles with oedema, apoptosis, necrosis, and foreign-body giant cells around the
affected follicles (Alkhalifah et al 2010). AA prevalence ranges from 13 to 53% and increases
with age, but the prognosis is no different from that of non-APECED AA. Patients experience
single or multiple recurrences of AA during their lifetimes (Collins et al 2006). AA is very
rarely  one  of  the  first  manifestations  of  APECED  (Perheentupa  2006).  Although  AA  is  not
lethal, it may impair the quality of life (QoL) of patients by affecting their body image.
AA appears to be a multifactorial disorder related to autoimmune targeting against the hair
follicle. Mouse models indicate that CD4+ and CD8+ T cell subsets are involved in the hair
loss promotion (Alkhalifah et al 2010). Other factors include genetic factors like DQB1*03
and DRB1*1104 (Alkhalifah et al 2010), as well as environmental factors like stress. Halonen
et al found a significant association with DRB1*04-DQB1*302 in APECED patients
(Halonen et al 2002). Lastly, intestinal malabsorption during APECED leads to underlying
hypoalbuminaemia and multiple vitamin deficiencies that can contribute to hair loss (Puzenat
et al 2010).
Abs against the hair follicle matrix, cuticle and cortex keratinocytes have been observed to be
significantly associated with total AA in APECED patients, while patients with patchy AA
did not have such Abs (Hedstrand et al 1999). The same team then found a significant
correlation between Abs against tyrosine hydroxylase (TH) and the occurrence of AA using
the sera of 94 patients (including 29 patients with AA). Forty-four per cent of the patients
presented such Abs, but the prevalence was higher in the group with AA (62%) compared
with those without (35%, p = 0.02) (Hedstrand et al 2000). TH is involved in the conversion
of tyrosine to L-dopa, which can be found in human hair follicles and cultured keratinocytes.
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The authors also observed a mildly reduced activity of the enzyme with the patients’ serum,
even though normal controls also showed this inhibition. The authors failed to find any
specific TH staining on human scalp using either TH Abs or APECED patients’ serum. They
hypothesised a possible autoimmune attack on the nerve-endings close to the hair follicles. A
more  recent  study  failed  to  show  any  association  between  TH  Abs  and  AA  (Bratland  et  al
2013). The role of such Abs in the pathophysiology of AA is speculative.
2.2.3.2. Vitiligo
Vitiligo is the most common depigmenting disorder, with a prevalence of approximately 0.5%
in the world population. The hallmark is a loss of epidermal melanocytes. The initial cause of
nonsegmental vitiligo is still debated but appears to involve immunologic factors, oxidative
stress, or a sympathetic neurogenic disturbance (Taïeb et al 2009). In vitiligo-associated
multiple autoimmune disease patients, the variants in the gene encoding NACHT leucine-
rich-repeat protein 1, or NALP1, were  recently  identified  (Jin  et  al  2007).   In  APECED,  the
prevalence of vitiligo ranges from 8 to 33 % of the patients (Figure 5). It may show a patchy
distribution, affect hair follicle areas (poliosis) and be responsible for the halo-naevi (Sutton)
phenomenon (Collins et al 2006). Vitiligo is very rarely the first manifestation of APECED
(Perheentupa 2006). It can be associated with AA and, similar to AA, it may impair the QoL
of APECED patients.
Anti-melanocyte Abs have been reported in APECED patients (Howanitz et al 1981). Abs
against aromatic L-amino acid decarboxylase (AADC) have been found with vitiligo in
patients  with  APECED.  The  clinical  relevance  of  these  Abs  is  uncertain.   Abs  against  TH
have been found to be more prevalent among patients with non-APECED nonsegmental
vitiligo (Kemp et al 2011), especially when the vitiligo is active. Among series of APECED
patients, no association with vitiligo has been demonstrated (Hedstrand et al 2000, Bratland et
al 2013). Kemp et al suggested that, given that TH is an intracellular enzyme, TH Abs
probably arise by exposure of the antigen following damage to melanocytes by either
oxidative stress or an autoimmune attack on the melanocytes. It is unlikely that the Abs have
any effect on the function of the enzyme. They may serve as markers for the melanocyte
disruption and/or a cellular response to TH (Kemp et al 2011).
Transcription factors SOX9 and SOX10 have been shown to be antigen targets of Abs in
APECED (Hedstrand et al 2001). They were found in 47% and 63% of the patients with
vitiligo, respectively. SOX9 and 10 are involved in the embryonic development of various
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organs. SOX9 would be a target by cross-reactivity while SOX10, which is expressed in
melanocytes, would be the main autoantigen.
Lastly, Husebye et al reported that 80% of the APECED patients with vitiligo had Abs against
AADC compared with those without vitiligo (43%, p = 0.021) (Husebye et al 1997). However,
AADC is mainly expressed in the central nervous system and the liver, but not in the skin.
The authors speculated that this could be due to a possible cross-reaction with tyrosinase.
Nevertheless, they failed to report whether the patients having TH Abs also had AADC Abs.
In a small  Italian study, Dal Pra et  al  (2004) found results similar to those of Husebye et  al
(1997). However, they mentioned that 6 out of 8 (75%) patients with vitiligo and/or chronic
hepatitis had Abs against AADC. Among the 6 patients for which data are available, it
appears that 3 had vitiligo and 3 others autoimmune hepatitis. The control group in this study
consisted of only 8 patients with vitiligo. Söderbergh et al found AADC Abs in 12 patients
with Addison’s disease without APECED and only one of these patients had vitiligo (8%)
(Söderbergh et al 2000).
Figure 5. Vitiligo universalis in a woman with APECED
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2.2.3.3. Nail dystrophy
Nail dystrophy is a bothersome symptom that is often reported in patient series. However, the
aetiopathogenesis is far from clear. In a series of 18 Irish patients examined by a
dermatologist, none had nail pitting or distinctive nail dystrophy (Collins et al 2006). All nail
changes were related to candidal infection (Figure  4). Nail infection is the most common
cause of nail dystrophy. According to Perheentupa, 22 to 50% of the Finnish APECED
patients may have had nail pitting without positive candidiasis on fungal culture (Ahonen et al
1990, Perheentupa 2006). ‘Nail dystrophy’ encompasses a large number of nail symptoms and
it is not clear whether the authors had ever considered other possible causes for nail pitting,
such as alopecia areata (LeBoeuf et al 2007, Puzenat et al 2010).
2.2.3.4. Gastrointestinal manifestations (autoimmune hepatitis excluded)
Chronic  atrophic  gastritis,  with  pernicious  anaemia  or  not,  affects  7  to  33%  of  the  patients
(Table  1). Chronic atrophic gastritis is an autoimmune disease affecting the gastric parietal
cells and intrinsic factor (IF). It eventually leads to gastric atrophy, which in turn is associated
with vitamin B12 deficiency and pernicious anaemia (PA, Biermer disease) (Toh et al 1997).
These patients have Abs against the sodium-potassium channel molecule of the parietal cells
in  the  corpus  and  fundus  of  the  stomach  (parietal  cell  Abs,  PCA).  The  process  starts  with
superficial gastritis, characterised by lymphocytic infiltration below the epithelium, leading to
a diffuse gastritis with lymphocytic infiltration extending to specific glands and to glandular
destruction (atrophic gastritis). As hydrochloric acid and pepsinogen-producing cells
disappear, so does the secretion of gastric IF. PA is thus the end stage of gastric immunologic
destruction, caused not only by the lack of IF, but also by Abs recognising the vitamin B12-
binding protein and preventing the subsequent translocation of vitamin B12 from the ileum to
circulation  (Toh et  al  1997).  The  circulating  Abs  reacting  with  parietal  cells  and  IF  may be
detected before any clinical symptoms (Perheentupa 2006, Betterle et al 1998).  PA usually
develops during early adulthood (Betterle et al 1998), although sometimes even during
childhood (Oliva-Hemker et al 2006); this differs from solitary PA, which is usually
diagnosed in the sixth decade (Toh et al 1997).
The clinical symptoms are those of a chronic lack of vitamin B12. They may include atrophic
glossitis with a smooth red beef tongue, diarrhoea, malabsorption, peripheral neuropathy,
degeneration of the spinal cord, and personality defects. The red cell count is low along with
macrocytosis, leukopenia, thrombocytopenia, and pancytopenia. Over the long term, PA may
lead to gastric carcinoid tumours and adenocarcinoma, and therefore regular screening by
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gastric fibroscopy should be instituted. Treatment includes only intramuscular injections of
vitamin B12 every 1 to 3 months and regular fibroscopy for gastric carcinoma screening
(Kluger et al 2013).
In contrast to the main organ-specific autoimmune symptoms of APECED, the GI symptoms
and their underlying pathogenesis are poorly understood. The prevalence of GI symptoms
(excluding hepatitis) is roughly estimated at up to 25%. Cohorts and review articles usually
describe GI manifestations as ‘diarrhoea’, ‘constipation’ and ‘malabsorption’ (Kluger et al
2013). On the other hand, isolated case reports and small series depict severe intestinal
involvement in children leading to malabsorption, multiple nutritional deficiencies, growth
impairment (Ward et al 1999) and possible death (Perheentupa 2006). Studies of GI function
with intestinal biopsies are rare. GI symptoms may be the first manifestation of APECED and
may be have various causes and, therefore, effective treatment will vary accordingly.
Chronic  diarrhoea  is  the  first  manifestation  of  APECED  in  5%  of  the  patients  and  severe
constipation in 2% (Perheentupa 2006), while malabsorption varies from 9 to 26%, depending
on the series (Kluger et al 2013). Approximately half of the Sardinian patients disclose
periodic intestinal dysfunction (Meloni et al 2012). The precise identification of the cause of
intestinal symptoms in association with APECED, i.e. abdominal pain, bloating, and recurrent,
watery or fatty (steatorrhoea) diarrhoea or constipation, constitutes a real challenge for the
physician as the cause is far from obvious. Several disorders may co-occur or may follow
each other over the lifetime. Therefore, each new episode may either be related to a
previously identified cause or to a new one that has not yet been diagnosed. Reports on
APECED patient cohorts often lack precision on this aspect and various criteria have been
chosen to define GI manifestations. Authors may also evaluate only one aspect of the GI
symptoms. For instance, Ahonen et al focused only on malabsorption defined as floating
stools and increased faecal fat excretion (Ahonen et al 1990); therefore, other causes of
diarrhoea in APECED patients may have been overlooked. Often, the precise cause of
malabsorption  has  not  been  analysed  (Ahonen  et  al  1990,  Zaidi  et  al  2009)  or  may  be
multifactorial (Proust-Lemoine et al 2010). The main cause of lower GI tract dysfunction
includes hypocalcaemia whether it is induced by HP or malabsorption of D vitamin, intestinal
infection or autoimmune enteropathy with circulating Abs against tryptophan hydroxylase 1
(TPH-1) (Kluger et al 2013). Moreover, oral calcium intake is responsible for constipation. In
the late 90s, Ekwall et al identified TPH as an intestinal autoantigen in APECED patients
(Ekwall et al 1998). TPH-1 is expressed in serotonin-producing cells in the central nervous
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system and intestine. In their series of 80 patients, they were able to relate ‘GI symptoms’ to
the presence of circulating TPH-1 Abs and also to the total absence of enterochromaﬃn cells
in the mucosa of the small bowel. TPH-1 Abs were detected in 90% of APECED patients with
GI symptoms (Ekwall et al 1998, Scarpa et al 2013) and sometimes preceded the clinical
symptoms. Other studies confirmed this association (Posovszky et al 2012, Scarpa et al 2013).
Nevertheless, up to 34 to 50% of the patients with such Abs do not have any GI symptoms
(Ekwall et al 1998, Scarpa et al 2013). Several studies have shown a link between the absence
of  EECs  and  the  occurrence  of  GI  manifestations  (Ekwall  et  al  1998,  Posovsky  et  al  2012,
Scarpa et al 2013) (Figure 6).
In addition, Sköldberg et al (Sköldberg et al 2003) identified Abs against histidine
decarboxylase expressed by EEC-like cells in the gastric mucosa. On the other hand, celiac
disease remains exceedingly rare among APECED patients (Betterle et al 1998), while to the
best of our knowledge inflammatory bowel disorders have not been reported. An exhaustive
list of GI diseases associated with APECED is summarised in Table 3.
Figure 6. The dopamine and serotonin pathway
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Table 3. A review of gastrointestinal manifestations in APECED (Kluger et al 2013)
Oesophagus
Candida oesophagitis
Oesophageal carcinoma
Stomach
Pernicious anaemia (Biermer’s anaemia)
Autoimmune gastric atrophy
Gastric adenocarcinoma
Gastric carcinoid tumour
Bowel
Primary hypoparathyroid-induced hypocalcaemia
Secondary hypocalcaemia due to malabsorption of vitamin D
Intestinal infection: bacterial overgrowth, Candida infection, Giardiasis lamblia, Clostridium
difficile
Exocrine pancreatic insufficiency (related to): hypocalcaemia, diabetes, celiac disease, cystic
fibrosis, Intestinal megaloblastosis due to vitamin B12 deficiency, autoimmune pancreatitis
(?)
Autoimmune enteropathy
Lactase nonpersistence / deficiency
Intestinal lymphangiectasia
Celiac disease
Functional disease
Autoimmune hepatitis
Cholelithiasis
(?) no cases reported in APECED thus far, but considered according to the pancreatitis
induced in the knock out Aire-/- mouse model (Ramsey et al 2002)
2.2.3.5. Hepatitis
Autoimmune hepatitis (AIH) affects 8 to 27% of APECED patients (Betterle et al 1998,
Obermayer-Straub et al 2001). Its spectrum ranges from asymptomatic and/or self-limited
cytolysis that may fluctuate over time to fulminant hepatitis with liver failure and potential
lethal outcome (Obermay-Straub et al 2001). Interestingly, the autoimmune targets are
different from those of the usual AIH type 1 and type 2. Usually, in type 1, patients disclose
antinuclear Abs and/or smooth muscle Abs and soluble liver antigen/liver pancreas antigen
(SLA/LP), while liver-kidney microsomal Abs (LKM-1 and LKM3) and liver cytosolic
antigen  (LC1)  are  the  biological  signs  of  AIH  type  2.  APECED  patients  have  a  different
variety of Abs mainly against cytochrome P4501A2 (CYP1A2), cytochrome P4502A6
(CYP2A6) and aromatic L-amino acid decarboxylase (AADC) (Husebye et al 1997, Dal Pra
et al 2004). According to Obermayer et al, anti-CYP1A2 is likely to be specific for APECED-
associated AIH; however, half of the patients with hepatitis do not have this Ab (Obermayer-
Straub et al 2001). CYP2A6 Abs would be more suitable for a diagnosis of APECED rather
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than AIH. In any case, the serological follow-up of an APECED patient with hepatitis clearly
showed an evolution in the Ab types and titres over time, with the appearance of new Abs
against cytochrome P450 (Obermayer-Straub et al 2001). Thus, anti-CYP1A2 Abs is likely to
parallel the severity of hepatitis. Other Abs of interest have been found to be associated with
hepatitis, but with sometimes conflicting results. For instance, Söderbergh et al found an
association with TPH Abs (tryptophan hydroxylase) but failed to find a statistical association
with AADC Abs, despite being present in 92% of the patients with hepatitis (Söderbergh et al
2004). TPH is not expressed in the liver (Söderbergh et al 2004). In the study by Bratland et al
on 48 Scandinavian patients, no link between hepatitis (20% of the patients) and TPH1 or 2
was found (Bratland et al 2013).
2.2.3.6. Hyposplenia and asplenia
The spontaneous regression of the spleen leading to functional asplenia is considered to be an
infrequent feature of APECED (Parker et al 1990, Pollak et al 2009). It occurs in 9% of the
affected 5- to 15-year-olds and in 19% of those over 17 years old (Perheentupa 2006), but its
prevalence  is  otherwise  poorly  documented.  Abdominal  ultrasound  and  CT  scans  can  show
the progressive regression in size of the spleen to complete atrophy over the course of patient
follow-up (Starzyk et al 2001). Blood anomalies such as thrombocytosis or Howell-Jolly
bodies on peripheral blood smears raise the suspicion of asplenia. Unmanaged asplenia
predisposes to potentially life-threatening fulminant S. pneumoniae or H.influenza sepsis.
Management includes patient education, regular self-administered oral antibiotic prophylaxis
and updated vaccination against S. pneumoniae and H.influenza (Husebye et al 2009).
The mechanisms of spleen reduction in APECED are not known. Aburano et al showed that
the sequestration function remained while the reticuloendothelial system was impaired in an
APECED patient (Aburano et al 1997). Immune destruction of the spleen has been suggested
but has not been confirmed (Friedman et al 1991).
2.2.3.7. Kidney manifestations
Renal impairment in APECED is rarely mentioned in large series of patients. Only a few
severe paediatric cases of renal failure leading to haemodialysis and transplantation with
sometimes acute and chronic rejection have been reported (Hannigan et al 1996, Ulinski et al
2006, Al-owain et al 2010). Betterle et al mentioned the death of an 18-year-old patient from
renal failure among their 41 Italian patients (1/41, 2.4%) without further detail (Betterle et al
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1998). Renal diseases associated with APECED include specific autoimmune
tubulointerstitial nephritis (TIN) that can manifest by renal tubular acidosis, nephrocalcinosis,
and chronic renal failure requiring kidney transplantation. Perheentupa estimated that up to
9% (8/92) of patients develop TIN (Perheentupa 2006). The suspected pathogenic mechanism
is immunity against tubular cells. Nephrocalcinosis may also be related to
hypoparathyroidism. In addition, T1D, hypertension and drug-induced nephrotoxicity, such as
from  cyclosporine  to  control  the  severe  autoimmune  manifestations  of  APECED,  can  be
additional causes of renal failure.
2.2.3.8. Lung manifestations
Respiratory-related symptoms are quite uncommon in APECED. In a large series of 110
European patients, Alimohammadi et al found only 7 with respiratory symptoms (6.4%)
(Alimohammadi et al 2009). The symptoms included recurrent lower respiratory infections,
obstructive respiratory asthma-like symptoms, chronic cough, dyspnoea, thoracic pain, and
airways hyperresponsiveness (Alimohammadi et al 2009). The disease is progressive with
worsening of the symptoms and chronic respiratory failure that in rare cases can be lethal (De
Luca et al 2008, Alimohammadi et al 2009). Some patients may develop lymphocytic
bronchiolitis with interstitial pneumonitis (Popler et al 2012). Only one case of rapidly lethal
primary pulmonary hypertension with no underlying pneumopathy was reported in a 30-year-
old APECED woman in Poland (Korniscewski et al 2003). However, a possible fortuitous
association cannot be ruled out.
Recently, the efficacy of anti-CD20 monoclonal Abs in a 9-year old patient with organising
pneumonia and lymphocytic bronchiolitis was reported (Popler et al 2012).
Abs against a potassium channel regulator named KCNRG has been shown to be present in
88%  of  the  patients  with  self-reported  respiratory  symptoms,  while  less  than  1%  of  the
APECED  patients  with  no  respiratory  complaints  had  this  Ab  (Alimohammadi  et  al  2009).
KCNRG is mainly expressed in the lung in the epithelial cells of terminal bronchioles. A
pathogenic link between the Abs and the symptoms is still open and KCNRG Abs may merely
reflect the autoimmune aggression of the terminal bronchioles. Besides, respiratory symptoms
may be related to other causes such as unrelated asthma, tobacco-related chronic bronchitis,
lung  infection  or  cystic  fibrosis.  It  could  be  useful  in  the  evaluation  of  an  APECED patient
with respiratory symptoms to distinguish a specific autoimmune pneumopathy from other
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conditions and to suggest the use of immunosuppressive therapies (Alimohammadi et al 2009;
Popler et al 2012).
2.2.3.9. Enamel dysplasia
Defective dental enamel formation of the permanent teeth is frequent and affects from 25 to
82% of the patients (Myllärniemi et al 1978; Perheentupa 2006). The pattern of enamel
involvement differs from patient to patient, ranging from horizontal hypoplastic patches/pitted
enamel surface of variable width alternating with zones of well-formed enamel, to complete
hypoplastic enamel. Usually all permanent teeth are hypoplastic but sometimes only
premolars and second molars are affected. Such hypoplasia exposes to further damage and
caries. Dental care is necessary and should be performed promptly. The occurrence
of enamel hypoplasia is independent of hypocalcaemia and hypoparathyroidism (Myllärniemi
et al 1978). Some authors have suggested the possibility of immune aggression against
ameloblasts  or  against  one  of  their  proteins  secreted  in  the  extracellular  matrix  as  potential
targets, but this hypothesis has never been explored (Pavlic et al 2009). Interestingly, Bratland
et al found also a statistical association between TH Abs and enamel dysplasia in a Norwegian
subgroup of patients with APECED, but these results need to be confirmed by larger series
(Bratland et al 2013).
2.2.3.10. Eye manifestations
Considered as one of the ‘ectodermal’ manifestations of APECED (Husebye et 2009), ocular
manifestations are also one of the most disabling as they can lead to severe visual impairment
and even complete blindness. Virtually any of the ocular structures can be affected, from the
eyelashes, the sclera and the cornea to the retina and even the optic nerve.
Ocular symptoms usually appear at a mean age of 5 years but with extreme variations from
early childhood to adulthood (Perheentupa 2006). They are the first manifestation of
APECED in only 4% of the cases (Perheentupa 2006).
The main manifestation is keratitis (or keratoconjunctivitis), whose prevalence is about 25%
(Gass 1962, Wagman et al 1987, Merenmies et al 2000, Perheentupa 2006). Higher
prevalences of 36% (Chang et al 2006) and even up to 52% have been reported in older
reviews (Gass 1962). The symptoms are those of any keratoconjunctivitis, including
photophobia, blepharospasm and lacrimation, conjunctival redness, sensation of sand in the
eyes and reduced lacrimation. Chronic evolution leads to subepithelial scarring, perforation
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(Yeh et al 2009), nodulus, leukoma and deep vascularisation. Keratitis is not considered to be
of fungal origin (Merenmies et al 2000).
An autoimmune mechanism has been suspected to be responsible for the immune aggression
of the eye. Local treatment relies on vitamin A and immunosuppressive treatments
(corticosteroid (Merenmies et al 2000), tacrolimus or cyclosporine (Chang et al 2006)).
Corneal transplant may be necessary to restore useful sight (Tarkkanen et al 2001). Low
corticosteroid maintenance is necessary although it does not always prevent recurrence
(Merenmies et al 2000).
The mechanism of the keratitis is poorly understood. An autoimmune attack of the
corneal/conjunctival epithelium has been postulated. Yeh et al recently showed that Aire-
deficient mice are prone to develop an infiltration of the conjunctival epithelium by CD4,
CD8 and CD11b+ and the Meibomian glands under dessicating stress with an increase in CD4,
CD8, CD11b+ and CD45 cells. In addition, conjunctival globlet cell density was lower in
Aire -/- mice (Yeh et al 2009). Goblet cells are mucin-producing cells that are critical to tear
film and ocular surface homeostasis, loss or reduction, associated with a severe ocular surface
phenotype. The Meibomian glands are involved in the production of the hydrophobic lipid
layer of the tear film, and disruption of the Meibomian function can also contribute to chronic
ocular surface disease. Recently, Laakso et al reported that several Finnish patients developed
flares of keratoconjunctivitis after a cutaneous Mantoux reaction was performed, stressing
that  keratoconjunctivitis  is  of  autoimmune  origin  and  has  nothing  to  do  with  an  ectodermal
‘dystrophy’ (Laakso et al 2014). DeVoss et al observed Abs against proteins present in and
around the ducts upon indirect immunofluorescence and identified an 18kDa protein, odorant-
binding protein 1a (OBP1a), a putative pheromone transporter belonging to the lipocalin
family, as a target of the Abs present in the tear fluid and the lacrimal glands (DeVoss et al
2010). Recently, another hypothesis was raised with a possible deficiency among the limbic
stem cells (Shah et al 2007).
Other ocular manifestations of APECED are summarised in Table  4. Briefly, reduced tear
production as assessed by Schirmer’s tests may develop even without any keratitis (Chang et
al 2006). The association with Sjögren’s syndrome has been reported in a few patients
(Betterle et al 1998). The development of cataract (18%) (Chang et al 2006) has been related
to  hypocalcaemia  (Rajendram et  al  2003).  The  retina  and  the  optic  nerve  can  be  affected  in
APECED (Orlova et al 2010). Autoimmune retinopathies are a rare group of heterogeneous
ocular diseases characterised by rapidly progressive, painless, unilateral or bilateral visual loss.
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A high number of retinal Abs has been identified as potential biomarkers but there are no
validated standardised methodological approaches (Braithwaite et al 2014). In APECED, Abs
against the retina and the optic nerve have been detected (Wood et al 1991). Anti-retinal Abs
were found in some patients with retinopathy (enolase, GAPDH, and other undefined targets
identified by western blots) necessitating oral immunosuppressive therapies. There is a high
number of other Abs against recoverin, enolase, rod transfucin, and numerous other targets
against photoreceptors, Müller cells, cones and rods that are possible targets. However, none
has ever been explored in APECED, and the direct pathogenicity of such Abs is debatable
because of the blood-retina barrier (Braithwaite et al 2014).
Table 4. Overview of the ocular manifestations of APECED
Specific manifestations
Keratoconjunctivitis
Dry eyes
Iridocyclitis
Retinitis pigmentosa (Orlova et al 2010)
Optic atrophy
Manifestations related to other autoimmune conditions during APECED
Cortical lenticular opacities/cataract secondary to hypoparathyroidism
Diabetic retinopathy
Hypotrichosis
Loss of eyelashes and/eyebrows due to alopecia areata
Sjögren’s syndrome
Vogt-Koyanagi-Harada syndrome (Jovic et al 1996)
Meibomian gland dysfunction (?)
Other
Myopia
Retinal detachment
Hypertrichosis
2.3. Genetics: AIRE Mutations
2.3.1. Autoimmune regulator gene
APECED is caused by loss-of-function mutations in the Autoimmune Regulator gene (AIRE),
identified in 1997 in the q22 region of chromosome 22 (Nagamine et al 1997; Finnish-
German APECED Consortium, 1997). The gene is approximately 13 kb in length and the
coding sequence is composed of 14 exons coding for a 58 kDa protein of 545 amino acids
(Nagamine et al 1997; Finnish-German APECED Consortium, 1997). AIRE presents domains
that are characteristic of transcription regulators and chromatin-binding proteins. It is similar
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to SP100-family proteins that are involved in DNA binding, modulation of transcription and
repression mechanisms (Peterson et al 2008).
AIRE contains
- an N-terminal six-helix structure caspase-recruitment domain (CARD) involved in
 the oligomerisation of AIRE
- a SAND domain that is a putative DNA-binding domain
- two plant homeodomains (PHD1 and PHD2) fingers involved in protein-protein
 interaction. PHD1 has been shown to mediate the binding of AIRE to non
methylated histone H3
- a prolin-rich region (PRR) involved in transcription
- The N-terminus also contains a nuclear localisation signal (NLS) for nuclear import
 of the protein, while the C-terminus is important for transcriptional activation
 (Arstila et al 2013) (Figure 7).
Figure 7. The structure of AIRE protein (adapted from Arstila et al 2013)
2.3.2. AIRE mutations and their implications in the phenotype
To date, over 60 mutations (nonsense, deletion or missense) have been localised in the AIRE
gene of APECED patients (Fierabracci 2011, Arstila et al 2013). It has been rather difficult to
draw definitive conclusions on genotype-phenotype correlation, since the number of
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mutations is high but the number of carriers for each mutation is low. In Finland, 83% of the
patients carry the so-called Finn major mutation R257X (c.769C>T) in exon 6, indicating a
founder effect in this geographically isolated population (Heino et al 2001) (Figure  3). The
mutation is not, however, restricted to the Finns as it is the most common mutation
worldwide. The other frequent mutation 967-979del13bp, a 13-base pair deletion (c.967-
979del) in exon 8, is more frequent among North American and British patients (Heino et al
2001). Except for one family in Italy (Cetani et al 2001), there is no dominant
mutation/dominant fashion transmission reported thus far, meaning the patient must be a
homozygous or heterozygous composite for the AIRE mutation to develop APECED.
Despite the growing number of reported APECED-causing mutations, the phenotypic
variations among APECED patients cannot be explained by allelic variation in the AIRE gene.
The typical example comes from the phenotypic variation in APECED among Finnish
patients, despite most of them being homozygous R257X. Variation in phenotype between
siblings indicates that other genetic or environmental factors determine the clinical severity of
the disease (Heino et al 2001, Arstila et al 2013).  Two clinical genotype-phenotypes are
nevertheless recognised: i) patients who have the R257X mutation do develop CMC (Halonen
et al 2002) and ii) and the Iranian Jews carrying the Y85C mutations have a milder form of
APECED. Compared with the Finns, the Iranian Jews do not present keratopathy or CMC
(Zlotogora  et  al  1992,  Heino  et  al  2001).  Other  genes,  such  as  the  HLA  class  II  alleles
(Halonen et al 2002), the gender of the patients and additional environmental factors may
influence the clinical phenotype of APECED.
2.3.3. AIRE functions
AIRE has been proposed to function as a nonconventional transcription factor with a certain
number of functions: DNA-binding, assembly into a large DNA-binding complex, induction
of elongation by recruiting the positive transcription elongation factor b (pTEFb), direct
binding to histone H3, and recruitment of genes to the nuclear matrix. Given the complexity
of AIRE functioning, many key questions remain unanswered (Fiebaracci 2011).
AIRE is expressed mainly in the thymus, but also in lymph nodes and foetal liver (Kluger et al
2012). The AIRE protein functions as a transcription factor (Peterson et al 2008, Gardner et al
2009, Fierabracci 2011). AIRE is mainly expressed in the medullary thymic epithelial cells
(mTECs) (Peterson et al 2008, Arstila et al 2013) and cells of the monocyte/dendritic cell
lineage (Kogawa et al 2002). mTECs through the expression of MHC classes I and II express
46
a  wide  array  of  tissue-restricted  antigens  (TRAs)  derived  from different  organs  in  the  body.
TRAs include self-proteins with patterns of expression restricted to a single or small handful
of organs. Thymic expression of TRA serves as an important source of self-antigens to allow
the negative selection of autoreactive T cells. Collectively, mTEC and thymic
monocyte/dendritic cells play a crucial role in establishing self-tolerance by eliminating
autoreactive T cells (negative selection) and/or by producing immunoregulatory FOXP3+ T
cells, which prevent CD4+ T cell-mediated organ-specific autoimmune diseases. Collectively,
several studies in mouse and man have shown that AIRE regulates thymic expression of
several genes of ectopic peripheral proteins including many TRAs. Thus, AIRE dysfunction
leads to a decrease in the expression of TRAs in the thymus, and consequently, autoreactive T
cell clones escape into the periphery (Derbinski et al 2005, Moraes-Vasconcelos et al 2008,
Gardner et al 2009, Fierabracci 2011). Besides, extrathymic AIRE expressing cells (eTACs)
in the secondary lymph nodes of mice are capable of expressing self-antigens and may delete
naive autoreactive T cells, reinforcing the immune tolerance by preventing the maturation of
autoreactive T cells that could escape thymic negative selection (Gardner et al 2008) (Figure
8).
Figure  8.  AIRE  in  human  immune  tolerance  in  the  thymus  and  the  periphery  (modified
from Proust-Lemoine et al 2012)
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2.4. Autoantibodies in APECED
2.4.1. Tissue-specific antibodies
Patients  with  APECED  may  disclose  a  multitude  of  tissue-directed  Abs  (Arstila  et  al  2013,
Table  2). The Abs are mostly directed against enzymes involved in hormone synthesis.
Interestingly, because those targets are mainly intracellular, the real impact on each disease
component is not clear. The precise mechanism of the production of autoantibodies in
APECED has not yet been elucidated. Lindh et al reported in a mouse model that Aire–/– mice
displayed a T cell-independent response against some antigens with autoantibodies. This
response  was  dependent  on  marginal  zone  B cells  in  the  spleen  (Lindh et  al  2008).  Such  an
exaggerated response was linked to increased levels of a cytokine, the B cell-activating factor
(BAFF) produced by dendritic cells. Interestingly, BAFF was also found to be elevated in
APECED patients (Lindh et al 2008). Therefore, a cell-intrinsic effect of AIRE deficiency in
peripheral DCs would lead to higher serum BAFF and enhanced activation of B cells,
especially in the spleen, making them more prone to produce autoantibodies, independently of
the autoreactive T cells (Lindh et al 2008). In addition, Campbell et al observed in a collagen-
induced arthritis model that Aire knock-out mice had increased CD4 T cell help to B cells for
cross-reactive Abs production (Campbell et al 2009). The CD4 T-cells were indeed more
efficient in this model at stimulating wild-type B cells to produce specific Abs against
collagen II (Campbell et al 2009).
Another hypothesis is that the circulating antibodies may simply reflect the autoimmunity
directed against a specific organ without being specifically involved in the pathogeny. The
tissue destruction preceding the failure of the endocrine organs may have a role. Tissue
destruction, caused by trauma, viral infection or a T cell-mediated autoimmune attack, would
probably lead to the release of potential tissue-specific autoantigens and, thus, to Ab
formation against these proteins in a patient with AIRE deficiency.
This aspect is important to take into account as it may explain why various publications report
the ‘statistical’ significance between certain Abs and symptoms or diseases, while the real
pathologic relevance remains rather unclear.
2.4.2. Anticytokine antibodies
Anticytokine Abs are a newly recognised cause of autoimmune and infectious diseases
(Browne et al 2010). Neutralising high-titre Abs can cause a wide variety of potentially life-
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threatening illnesses (Browne et al 2010). Thus, Abs against interferon gamma, erythropoietin,
G-CSF or GM-CSF have been described (Browne et al 2010). APECED is definitely the
prototype of a disease with circulating anticytokine Abs.
2.4.2.1. Interferon alpha autoantibodies
The presence of anti-IFN type I Abs in APECED was first reported by Meager et al in 2006
(Meager et al 2006), and then confirmed by others (Meloni et al 2008). All the patients of
their series (76/76) had neutralising IgG Abs against IFN-a subtypes compared with none in
the controls. These Abs can be detected early in life (even before the age of 1 year),
antedating or coinciding with CMC infection or other autoimmune features (Wolff et al 2013),
and they remain positive for decades (Meager et al 2006). Overall, 90% of APECED patients
have Abs against IFN-a and 100% against IFN-w (Kisand et al 2011). The precise role and
the impact of such Abs on the disease pathogenesis are not known. There is no relationship
between the clinical phenotype or the AIRE mutation (Meloni et al 2008, Wolff et al 2013).
Abs against IFN-a cause highly significant down-regulation of interferon-stimulated gene
expression in the T cells in APECED patients' blood (Kisand K et al 2008). Despite this high
activity, the Abs do not predispose patients to an increased risk of viral infections. It is
possible that other IFNs such as type II or III or IFN-b compensate for such a deficiency. It
may also be that the biological tests are ‘too’ sensitive and overestimate the in vivo biological
activity  in  addition  to  APECED  (Kisand  et  al  2011).  To  date,  the  anti-IFN  Abs  have  a
diagnostic value as, apart from APECED, they are found only in thymoma-associated
myasthenia gravis (Kisand et al 2011). Abs against IFN-b, l1 and other interleukins such as
IL-10 and -12 were found at low non-neutralising levels in APECED patients (Meager et al
2006).
2.4.2.2. Interleukin-17A, -17F and -22 autoantibodies
Neutralising Abs against IL-17 and IL-22 are also present at diagnosis or earlier and persist
for  decades  at  high  titres  in  APECED  patients.  As  for  Abs  against  IFN-a, these Abs can
precede the occurrence of any clinical symptoms in siblings with AIRE mutations (Wolff et al
2013). A strong association with CMC has been shown (Kisand et al 2010, Puel et al 2010).
Kisand et al found anti-IL-17A, -IL-17F and IL-22 in 41%, 74% and 90% of their 162
APECED patients, respectively (Kisand et al 2010).  Puel et al identified anti-IL-17 Abs in 33
APECED patients, including 29 with CMC, whilst controls had no Abs. The Abs were able to
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inhibit the production of IL-6 from IL-17-responsive fibroblasts (Puel et al 2010). In only a
few  cases,  patients  with  such  Abs  did  not  have  any  CMC.  Conversely  to  IFN-a, the
production of IL-17F and -22 is especially impaired in patients with such Abs (Kisand et al
2011). Nevertheless, there are numerous causes of CMC other than APECED, and therefore
IL-17 and IL-22 Abs are not absolutely necessary for the development of CMC. Besides,
there are notable cases of APECED patients with CMC and without any Abs against IL-17F
or IL-22 (Wolff et  al  2013).  Laakso et  al  recently showed a defect in expression of IL-22 in
the  skin  of  APECED  patients  in  a  steady-state  resident  population  and  in  the  cells
participating in a tuberculin-induced recall response (cf below, Laakso et al 2014). An IL-22
defect is likely to be a contributing factor in CMC in APECED patients (Laakso et al 2014).
2.4.3. Cell-immune responses in APECED
It is generally believed that the destruction of the endocrine organs in APECED is caused by
the autoreactive CD8+ cytotoxic T cells, although definitive evidence for this mechanism is
still lacking (Betterle et al 2003, Moraes-Vasconcelos et al 2008). This hypothesis is
reinforced by microscopic examination of samples, sometimes obtained postmortem.
Typically, the parathyroid, adrenal glands or ovaries show atrophy and lymphocytic
infiltration that suggest a cell-mediated attack leading to atrophy and dysfunction (Betterle et
al 2003). This is also highlighted, indirectly, by the analysis of the Aire–/– mice, which also
develop lymphocytic infiltration in some inner organs along with atrophy (Ramsey al 2002).
Immunological studies have stressed an increased frequency of CD8+ CD45RA+ CCR7-
effector T cells in the blood (Laakso et al 2011). On the other hand, immune regulation is also
defective in APECED as illustrated by the decreased number of T regulatory cells (T reg,
CD4+ CD25+ Foxp3+), especially the CD45RO+-activated subset (Ryan et al 2005, Laakso
et al 2010). Whether the T reg deficiency is related to thymic AIRE deficiency  per  se  or  is
secondary to the severe autoimmune disease in the patients is unknown.
Laakso et al recently showed a defect in the expression of IL-22 in the skin of APECED
patients (Laakso et al 2014). The Th22 population was the main affected population, even
though IL-17 production was also seen to be impaired. It is not known to what extent the
circulating Abs against IL-22 and the T reg activation deficiency are involved in the IL-22
defect (Laakso et al 2014).  It was recently suggested that the pathogenic T cells are primed
before their export from the AIRE-deficient thymus (Kisand et al 2014).
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Overall, APECED is now seen as a disease with both increased T cell effector and decreased
regulator activity (Arstila et al 2013). However, the defective negative selection of
autoreactive clones in AIRE-deficient thymus cannot, by itself, explain fully the autoimmune
symptoms of APECED.
The  various  subclasses  of  anomalies  of  the  peripheral  immunocompetent  cells  reported  in
various series are summarised in Table  5 (Wolff et al 2010). However, it is important to
remember that such results are often variable, mostly because of variation among the study
populations in terms of disease duration or activity at the time of the immunophenotyping
(Wolff et al 2010).
Table 5. Immunocompetent cells and immunoglobulin anomalies observed in APECED
T cells
CD3+; CD4+; CD8+ normal rate
Memory T cells (CD4+CD45RA-CD45RO+) diminished
Th17
subset CD4+CCR6+CXCR3+: diminished
T regulatory cells
T reg (CD4+CD25+FoxP3+) cells diminished
T reg subset (CD3+CD4+CD25+CD127-) diminished
B Lymphocytes
B-cell CD19+ : normal
NK Cells
NKT cells (CD3+CD56+) normal or decreased
NK cells (CD3-CD56+) normal
Monocytes
CD14+/live cells normal
CD14+CD16+/CD14+ cells diminished
Dendritic cells
Normal
Immunoglobulins
Increased serum IgM, IgG, IgE; deficiency in IgA
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3. Quality of life
3.1. APECED
It has been well-established that health-related quality of life is impaired in chronic diseases.
In the field of endocrinology, numerous studies have shown that T1D, hypothyroidism and
Addison’s disease have an impact on the HQoL of patients before any medical intervention.
Patients with APECED find themselves in a very peculiar situation, due to the unique
accumulation of mainly endocrine diseases and the early onset in childhood. Early in life, oral
CMC impairs food intake and the pleasure of eating (López-Jornet et al 2009; Liu et al 2012).
Later on in adulthood, the sex life of the women with genital candidiasis is affected. Some of
the endocrine diseases, namely AD, HP and HT, expose to potentially lethal complications
(adrenal crisis, hypocalcaemia and coma in cases of untreated hypothyroidism). This
underlines the importance of educating patients and local healthcare providers to detect early
symptoms and manage any complications. Autoimmune hepatitis, bronchiolitis or TIN, albeit
rare, may rapidly become lethal if not controlled by immunosuppressive therapy. Asplenia
exposes to fulminant sepsis and, lastly, immunosuppressive treatment increases the risk of
sepsis  as  well  as  other  side  effects.  The  risk  of  infertility  is  a  burden  for  young  women.
Preventive measures, such as early pregnancy in young adults or cryoconservation of oocytes,
cause additional stress. The patients are also exposed to the risk of developing oral squamous
cell carcinoma, while atrophic gastritis exposes to gastric carcinoma. Hormonal imbalance of
thyroid function or adrenal glands typically may interfere with mood and general well-being
as well. Diabetes type 1 alone exposes to a high number of complications such as the macro-
and microangiopathies.
All these diseases also imply the need for regular follow-up, blood test monitoring,
multidisciplinary management and oral intake of numerous hormones and supplements.
Keratoconjunctivitis may lead to severe visual impairment, and skin manifestations such as
vitiligo or alopecia areata can be additional causes of stress, negatively affecting the body
image of the patient. Therefore, exploring the impaired quality of life in APECED patients
seems amply justified (Figure 9).
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Figure 9. A simplified view of how APECED can impact patient quality of life
3.2. Addison's disease and APS-2
AD accounts for approximately 80% of all cases of adrenal insufficiency. In recent years,
many  studies  have  shown  that  both  QoL  and  life  expectancy  are  reduced  in  AD  (Arlt  et  al
2003, Betterle et al 2011, Schalin-Jäntti 2011). Too small as well as too large doses of
hormone replacement (cortisol, aldosterone) therapy affect the patient's well-being.  In recent
years, many studies have demonstrated that the doses previously recommended for cortisol
replacement have been much too large (Arlt et al 2003). In addition, timing of the dosage may
not be correct. Non-optimal replacement therapy may thus have a strong impact on QoL, both
on  personal  and  professional  levels  (Arlt  et  al  2003).  The  adverse  effect  of  chronic  adrenal
insufficiency on QoL is comparable to that of congestive heart failure (Løvås et al 2002).
Fifty percent of the patients with primary adrenal insufficiency considered themselves unfit to
work and 30% needed household help (Arlt et al 2003). Patients with adrenal insufficiency
show a significantly impaired HRQoL, irrespective of age, sex, concomitant disease and
primary or secondary origin of the disease (Hahner et al 2007). The QoL may also depend on
the condition that underlies the chronic AI (Reisch et al 2011). It is not known whether
Finnish AD patients suffer from impaired QoL and to what extent, and whether replacement
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doses, timing and surveillance at healthcare centres versus specialist centres influence these
factors.
Patients with AD have a life-long risk for potential acute emergencies during stressing
conditions, ranging from infections to surgical procedures and labour. Such conditions may
precipitate an acute adrenal crisis that can be lethal in the absence of correct management
(Schalin-Jäntti 2011). It is generally believed that AD patients may therefore have to visit
emergency healthcare facilities and frequently warrant hospital care. Whether this is the case
for Finnish AD patients is not known.
Fertility may be affected by AD, although it is primarily due to primary ovarian failure.
Indeed, AD and primary ovarian autoimmune failure do share common autoantibodies against
21-hydroxylase (Hoek et al 1997, Husebye et al 2009 b). Gonadal failure has been identified
in  approximately  17%  of  the  patients  with  APS  type  1  and  in  3.6%  of  patients  with  type  2
cases (Kowal et al 2006).
Depression and psychological/psychiatric disorders have been reported in patients with AD
(Virtanen et al 1998, Thomsen et al 2006). Depression may even be the presenting sign
(Virtanen et al 1998). Patients with AD may disclose increased levels of anxiety and fear and
overreaction to stimuli, but decreased performance efficiency and need for social contact.
Such psychological characteristics may affect the doctor-patient relationship, leading
potentially to poor compliance and less efficacious therapy.
Lastly, the persistent risk of developing new autoimmune disorders (such as thyroid
dysfunction, type I diabetes, celiac disease or vitiligo), the risk of possibly life-threatening
adrenal crisis that may occur at any time and may be misdiagnosed, and the necessity of
continuous hormone substitution can be sources of continuous distress.
Overall, all these factors may have a deep impact on the QoL of patients presenting with AD.
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AIMS OF THE STUDY
APECED is a monogenic disease manifesting as chronic candidiasis and a high number of
autoimmune disorders. Our objective was to better delineate the clinical manifestations of two
‘minor’ components of APECED that have been sparsely studied in the literature: the
gastrointestinal and nephrologic manifestations. We also reviewed the implication of Abs
against NALP5 and CaSR in hypoparathyroidism as well as other more common Abs during
APECED. Lastly, we investigated the impact of APECED on patient HRQoL and tried to
determine which factors are most involved.
Specifically, the aims were:
To study in detail the gastrointestinal and nephro-urologic manifestations among Finnish
APECED patients.
To investigate the occurrence and association of various Abs and the clinical manifestations,
mainly the gastrointestinal and renal manifestations.
To study the significance of parathyroid-directed Abs in APECED.
To study the occurrence of common non-tissue-specific Abs in APECED.
To evaluate the health-related quality of life among Finnish APECED and Finnish patients
with Addison’s disease/APS2 and to explore which factors may be specifically involved in the
QoL impairment.
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SUMMARY OF MATERIAL AND METHODS
The material and methods are described in greater detail in the original publications.
1. Patients and patient recruitment
In 2010-2011, we had track of 51 patients living with APECED, scattered all over the country
(Rönn 2014, unpublished observations). Most were members of a patients’ association
founded in 1995 (the Finnish registered APECED and Addison’s association: Apeced ja
Addison Ry). The association provides peer support and information to patients in the form of
meetings, information leaflets and a web page (http://www.apeced.org). The association also
has a permanent support person for eventual crises, trained by the Finnish Red Cross. The
Finnish patient group has a history of willingly participating in research on their disease. Thus,
the APECED patients were recruited through the association circuit between 2011 and 2013.
The number of patients for each study varied according to their availability, varying from 26
(Original study V) to 44 patients (Original study III). This explains the discrepancies between
published cohorts as regards gender, age, clinical manifestations and other outcomes. The
cohorts had a mean age ranging from 33 (Original study III) to 41 years (Original study V)
with female predominance (Original studies I to V). In addition, Rönn conducted a national
survey between 2010 and 2011 regarding the self-assessment of diseases and clinical
symptoms among Finnish patients with APECED. A database was established for this and
used as a reference for the studies of this thesis as well (Rönn 2014).
For AD and APS2 patients (Original study VI), we included 107 patients who had been
diagnosed and treated at the Helsinki University Central Hospital (Meilahti, Jorvi and Peijas
hospitals) from 1997 onwards and from the national patients’ organisation. Patient charts with
the ICD code for Addison’s disease (E27.1, E27.1 or E 27.4) and the questionnaires from
subjects recruited via the patients’ organisation were screened by an endocrinologist and only
subjects fulfilling the diagnostic criteria for AD were included in the study. APS-2 was
defined  as  patients  with  AD  associated  with  at  least  one  of  the  following  additional
autoimmune conditions: hypo- or hyperthyroidism, T1D, ovarian failure, celiac disease,
pernicious anaemia/atrophic gastritis, vitiligo or alopecia areata. The characteristics of the
patients for each study are summarised in Table 6.	
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Table 6. Patient characteristics in studies I to VI
Study n Female/Male  Median age in years
(range)
Diseases
I 31 21/10 40 (5-65) APECED
II 30 20/10 45 (7-68) APECED
III 44 26/18 33* (8-67) APECED
IV 30 20/10 42 (7-65) APECED
V 26 19/7 44 (17-65) APECED
VI 107 84/23 51 (22-76) AD and APS2
43 28/14 48 (22-73) AD
64 55/9 52 (23-76) APS2
*For this study only the mean age of the cohort is available
2. Interviews
For 3 studies (Original studies II, V and VI), we used self-reported questionnaires.
For Original study II, the questionnaire explored the past or present history of urinary tract
infections (pyelonephritis, cystitis, number of episodes), kidney or urinary tract stones, TIN,
renal biopsies, hypertension and uveitis. In addition, male patients were specifically asked if
they had previously been diagnosed with prostate disease (acute/chronic prostatitis, adenoma
or cancer). In order to ensure good comprehension and to avoid misunderstandings, the
questions used both medical terms and an explanatory definition of their meanings. The
questionnaire was mailed with an explanatory letter describing the intended research and
prepaid return envelopes. No second attempt was made to contact non-responders.
For Original study V, 3 self-reported questionnaires, for which a Finnish translation has been
validated, were used: the SF-36 (or RAND-36), Raitasalo’s modification of the short form of
the Beck Depression Inventory–BDI (RBDI) and the Dermatology Life Quality Index
(DLQI). The questionnaires were mailed along with an explanatory letter, an informed
consent  form  and  a  prepaid  envelope  for  return  of  the  questionnaire.  In  the  case  of  no
response, patients were contacted a second time by phone.
Because of the high number of possible GI symptoms, we chose for Original study I a direct
interview or a telephone interview by a single physician (Martta Jokinen), using a structured
questionnaire developed by Nicolas Kluger and Annamari Ranki. For children, one of the
parents was asked to answer the questions. The questionnaire included demographic data,
familial and personal GI conditions (including e.g. lactose intolerance and celiac disease) and
symptoms. The upper GI tract symptoms included sensation of dry mouth, pain with
swallowing (odynophagia), difficulties in swallowing solid and liquid food (dysphagia),
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vomiting, retrosternal pain and discomfort. The lower GI tract symptoms included
chronic/repeated episodes of constipation and/or diarrhoea, stool consistency, anal
incontinence and use of laxatives for constipation and pancrelipases for pancreatic exocrine
failure. Past history or active chronic mucosal candidiasis and organ-specific autoimmune
manifestations were also collected.
For Original study VI, apart  from the HRQoL questionnaires, we recorded current hormone
replacement therapy and dosage (hydrocortisone, HC or prednisone, fludrocortisone, FC,
dehydroepiandrosterone DHEA), social and demographic information, current weight and
height, blood pressure, other chronic comorbidities such as hypertension, coronary heart
disease, type 2 diabetes, thyroid dysfunction, and other autoimmune diseases, affiliation with
the  patients’  association,   and  current  level  of disease follow-up in the healthcare system
(university hospital/specialist in endocrinology, general hospital/specialist in internal
medicine or local healthcare centre/general practitioner). The questionnaires were mailed
along with an explanatory letter, an informed consent form, and a prepaid envelope for return
of the questionnaires.
3. Clinical records
We recently created a clinical database of APECED patients, including demographic data
(gender, age, age at APECED diagnosis, age at first onset of symptoms), clinical symptoms,
autoimmune endocrine and nonendocrine diseases, and occurrence of oral carcinoma or other
malignancies (Rönn 2014, unpublished observations), which allowed us to compare these
findings with the renal and urinary findings (Original study II). In the case of discrepancies or
unclear data, we collected information directly from the patients’ medical files, as authorised
by the patients themselves by written consent.  In a few cases,  the responsible physician was
directly contacted by one of us to cross-check the clinical data and the patients’ narratives.
4. AIRE mutations
All  the  patients  with  APECED  had  confirmed  mutations  of AIRE genes.  Among  the  44
patients included in Original study III, the exon 6 AIRE mutation c.769C_T was found in all
of them (100%), and 36 (82%) were homozygous for the allele. The mutation analyses were
done in the laboratories of the late Professor Leena Peltonen-Palotie, National Institute of
Health,  and  Professor  Kai  Krohn,  University  of  Tampere.  Other AIRE genotypes are
summarised in Table 7.
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Table 7. AIRE mutations in 44 APECED patients described in Original study III
AIRE mutation n (%)
c.769C_T/ c.769C_T 36 (82%)
c.769C_T/c.967–979del13bp 3 (6.8%)
c.769C_T/c.923G_A (C311Y, in exon 8) 2 (4.5%)
.769C_T/c.1638A_T (X546C, in exon 14) 1 (2.3%)
c.769C_T/11631164insA (M388fsX422, in exon
10)
1 (2.3%)
c.769C_T/undetermined allele 1 (2.3%)
5. Quality of life (Original studies V and VI)
To assess the impairment of the HRQoL of APECED patients (Original study V), 3
questionnaires were used. The SF-36 is one of the most widely used HRQoL survey
instruments  in  the  world  today  (Hays  et  al  1993).  It  is  a  self-rated,  profile-based  HRQL
measure and originates from the Medical Outcomes Study 36-item short-form health survey.
It comprises 36 items that assess 8 health concepts: physical functioning (10 items), physical
role limitations (4 items), emotional role limitations (3 items), social functioning (2 items),
bodily pain (2 items), general mental health/emotional well-being (5 items), energy/vitality (4
items), and general health perceptions (5 items). We used the Finnish version of the SF-36 as
it was shown to have good reliability and construct validity in the general Finnish population
(Aalto et al 1999). The SF-36 is scored in 2 steps. Each item is first scored on a scale from 0
to 100 (a higher score defining a higher HRQL), and an average value is calculated for each
of the 8 dimensions. If more than 50% of the items in a dimension are missing, the average
value cannot be calculated (Hays et al 1993).
The RBDI mood questionnaire (Beck et al 1972; Beck et al 1974) is a self-reported
questionnaire that has been used in Finland for the past 30 years for depression. This Finnish-
modified version of Beck's 13-item depression scale has 13 questions for depression
(Raitasalo 2007). Depression items are scored from 0 to 3 and the total score ranges from 0 to
39 points; 5 to 7 points indicates mild depression, 8 to 15 points moderate depression, and
over 16 points severe depression.
The DLQI® is the first dermatology-specific quality of life instrument and the most
frequently used instrument in studies of randomised controlled trials in dermatology (Finlay et
al 1994). It is a simple validated 10-question questionnaire which has been used for 33 skin
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conditions and is available in Finnish [20]. Patients respond on the basis of the symptoms they
may have presented in the previous week to permit accurate recall. Each question has 4
possible answers for a maximum of 3 points and a total maximum score of 30. Higher scores
indicate more severely affected QoL. The patients were given 3 DLQI questionnaires to
assess  the  differential  effects  of  alopecia,  vitiligo  and  CMC.  A  score  of  0  to  1  indicates  no
effect on the patient's life, 2 to 5 a small effect, 6 to 10 a moderate effect, 11 to 20 a very large
effect, and 21 to 30 an extremely large effect.
Questionnaires were not anonymous for the purpose of enabling comparison with the data in
the recently created clinical database (see chapter 3).
For the study of the QoL of patients with AD (Original study VI), we used 2 scores: the SF-36
and the 15D. The 15D is a generic, comprehensive, 15-dimensional, standardised, self-
administered measure of HRQoL that can be used both as a profile and as single index
instrument (Sintonen 2001). It is a well-validated test consisting of 15 dimensions: mobility,
vision, hearing, breathing, sleeping, eating, speech, elimination, usual activities, mental
function, discomfort and symptoms, depression, distress, vitality and sexual activity. Each
dimension is divided into 5 ordinal levels, by which more or less of the attribute can be
distinguished. The patient or person chooses the level best describing his or her current health
status for each dimension. The evaluation system of the 15D is based on an application of the
multi-attribute utility theory.  A set  of utility or preference weights,  elicited from the general
public through a 3-stage evaluation procedure, is used to generate the within-dimension level
values and the overall  utility score,  that  is,  the 15D score (single index number) over all  the
dimensions on a 0–1 scale. The maximum score is 1 (no problems on any dimension) and the
minimum score is 0 (equal to being dead). The minimal clinically important difference of the
15D score is 0.03. The advantage of the 15D is that the results of the patients were compared
with HRQoL data of an age- and sex-matched general Finnish population (n = 5671),
available from the National Health 2000 Health Examination Survey.
6. Routine laboratory tests (Original study II)
Laboratory analysis included recent (less than a year old) plasma creatinine, urea nitrogen,
plasma cystatin C, urinary proteins, low-molecular-weight protein and glucose values, a
urinalysis, a urine bacteriology and the value for prostate-specific antigen for men. The
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glomerular filtration rate (GFR) was assessed using the Cockcroft–Gault formula for adults or
the bedside Schwartz equation for children.
7. Tissue samples and immunohistochemistry
7.1. Gastrointestinal tissues (Original study I)
Archival formalin-fixed, paraffin-embedded biopsies from the upper (duodenum) and lower
GI tract (ileum, colon or rectum) were available from 12 patients (20 tissue samples
altogether), obtained during fibroscopy/colonoscopy for various symptoms (retrosternal
pain/dysphagia/oesophagitis, gastritis, constipation, diarrhoea, swollen abdomen).
7.2. Renal tissues (Original study II)
Three patients had undergone kidney biopsies. Archival formalin-fixed, paraffin-embedded
biopsies could not be traced in one patient and a second sample was too small  to allow any
valuable reinterpretation. Therefore, only one representative biopsy sample was available for
the study and the review of the histologic and immunofluorescence results.
7.3. Immunohistochemistry (Original study I)
Immunohistochemistry was performed as follows. After antigen retrieval (heating in citrate
buffer  at  pH  6  for  10  min),  the  tissue  sections  were  incubated  overnight  at  +4°C  with
monoclonal Abs against human defensin 5 (hD5, dilution of 4µL in 1 mL, clone 8C8; Thermo
Scientific, Rockford, IL, USA), CgA (dilution 1:400, Clone DAK-A3; DakoCytomation,
Glostrup, Denmark), 5-HT (dilution 1:200, NB120-16007, Novus Biologicals, Cambridge,
UK), villin (1:200, Clone 1D2 C3; DakoCytomation, Glostrup, Denmark), and interleukin-17
(IL-17, dilution 1:50, AF-317-NA, R&D Systems, Minneapolis, MN, USA). The bound Abs
were detected with the ImmPRESS Universal Ab (anti-mouse Ig/anti-rabbit Ig,
peroxidase) Polymer Detection Kit and AEC SK 4200 (Vector Laboratories Inc., Burlingame,
CA, USA) for CgA, 5-HT, hD5 and villin Abs and the VECTASTAIN Elite ABC Kit (Goat
IgG) PK-6105 and AEC SK 4200 (Vector Laboratories Inc., Burlingame, CA, U.S.A) for IL-
17 Abs. Normal healthy duodenum, ileum and colon sections from elective surgery patients
were used as reference samples. CgA, 5-HT, and IL-17 positive cells were calculated in 3
different areas per slide, selected randomly and bounded by 50 crypts in well-oriented
duodenal, ileal or colonic samples. If the sample contained fewer than 50 crypts, the number
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was normalised to 50 crypts. Villin expression was analysed according to the patterns of
reactivity in the enterocytes: brush borders (apex), cytoplasmic and/or basal expression.
8. Autoimmune and autoreactive T cells
8.1. Detection of tissue antigens recognised by patient sera and antibodies
8.1.1. Detection of autoantibodies against intestinal structures by indirect
immunofluorescence (IIF, Original study I)
Formalin-fixed, paraffin-embedded biopsies of normal human duodenum and ileum were used
as target tissue. After antigen retrieval (as above) and blocking with 1% BSA (bovine serum
albumin),  the  slides  were  incubated  for  1  hr  at  room  temperature  with  each  patient
serum (1:10 in phosphate-buffered saline, PBS) or with serum from healthy blood donors (n=
15, Finnish Red Cross blood service), washed in PBS, followed by FITC-conjugated anti-
human IgG (F0203; DakoCytomation, Glostrup, Denmark) at 1:40 for 30 min at room
temperature. The nuclei were visualised with DAPI (4',6-diamidino-2-phenylindole,
Vectashield®, Vector Laboratories Inc., Burlingame, CA, USA), after which the slides were
analysed with an Olympus BX50 microscope.
8.1.2. Detection of autoantibodies against renal structures by indirect
immunostaining of rat kidney (Original study II)
Indirect immunostaining of formalin-fixed, paraffin-embedded rat kidney (original study II)
sections was performed to detect tissue-specific cross-reactive Abs. Abs are typically cross-
reactive, and rodent tissues can be used for their detection (Fetissov et al 2009). Tissue
sections were deparaffinised, and the endogenous peroxidase activity was quenched with 1:10
hydrogen peroxide. Antigen retrieval was performed by heating slides in citrate buffer at pH 6
for 10 min.  Blocking was performed with 1% BSA. Slides were incubated overnight at +4°C
with individual patient sera (1:1000 in PBS). As a detection system, the VECTASTAIN Elite
ABC Kit (Goat IgG) PK-6105 and AEC SK 4200 (Vector Laboratories Inc., Burlingame, CA,
USA) were used. As control tissue, rat spleen sections, immunostained simultaneously on the
same slide, were used. Sera from healthy individuals served as control sera.
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8.2 Detection of circulating antibodies by enzyme-linked immunosorbent
assay (Original studies I and II)
Patient sera were collected between 2010 and 2012 and stored at −70°C.  We analysed Abs
against IFN-a (a1beta, a2beta, a4, a5), -g, -w, IL-17A, IL-17F, IL-22, and IL-23, and
against various intestinal autoantigens of interest: TPH-1, AADC, gastrin, AIE-75 and villin,
with  a  validated  in-house  ELISA  assay.  Plates  were  coated  with  recombinant  human
INF-a,-g, -w, IL-17A, IL-17F, IL-22, and IL-23 (ImmunoTools GmbH, Friesoythe,
Germany), TPH-1 (Sino Biologicals, Beijing, China) and villin (Novus Biologicals,
Cambridge, UK) with 0.75 µg of protein/ml in PBS, pH 7.0, blocked with 2% HSA. AIE-75
(Novus Biologicals, Cambridge, UK) and AADC (Nordic BioSite, Helsinki, Finland) were
used at 1 mg/ml concentration and gastrin (Novus Biologicals, Cambridge, UK) at 30 µg/ml
in  PBS with  pH 7.0.   The  precoated  plates  were  then  incubated  with  patient  serum samples
(1:250 dilution) for 2 hr at 22°C, washed,  and developed with anti-human IgG horseradish
peroxidase conjugate (Sigma-Aldrich),  1-Step Ultra TMB-ELISA (ThermoScientific,
Rockford, IL, USA) and Stop Solution (2M, H2SO4). Absorbance was read at 450 nm. Sera
from 53 to 62 healthy age- and sex-matched (except for children) blood donors, provided by
the Finnish Red Cross blood service, served as controls. The cut-off value was defined as
mean + 3SD.
8.3 Detection of CaSR and NALP5 antibodies (Original study III)
The following experiments were performed by Kemp et al in the University of Sheffield,
United Kingdom. Immunoprecipitation (IP) assays for detecting CaSR Abs were carried out
using CaSR-FLAG protein expressed in human embryonic kidney 293 cells (HEK293,
ECACC, Public Health England, Salisbury, UK): Proteins immunoprecipitated from the
HEK293 cell extract containing expressed CaSR-FLAG protein were separated by SDS-
PAGE in 7.5% (w/v) polyacrylamide gels and transferred to Trans-Blot® Transfer Membrane
(Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). The CaSR-FLAG protein was detected
using Anti-FLAG® M2-Peroxidase Conjugate (Sigma-Aldrich) and an ECL™ Western
Blotting  Analysis  System.  The  results  were  compared  by  immunoprecipitation  of  CaSR-
FLAG  anti-CaSR  Ab,  APECED  patient  sera,  control  sera  and  no  serum  or  anti-CaSR  Ab
(beads alone).
A CaSR antibody index for each serum was calculated as: densitometry value of tested
serum/mean densitometry value of a population of healthy control sera. Each serum was
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tested in at least 2 experiments and the mean CaSR antibody index was calculated. The upper
limit of normal for the CaSR immunoprecipitation assay was calculated using the mean CaSR
antibody  index  +  3SD  of  a  population  of  healthy  individuals.  Any  serum  with  a  CaSR
antibody index above the upper limit of normal was designated as positive for CaSR
antibodies.
NALP5 Abs were detected in radioligand binding assays (RBAs) using [35S]-labelled NALP5.
The latter was produced in vitro in  a  TnT®  T7-Coupled  Reticulocyte  Lysate  System
(Promega, Southampton, UK) and then used in radioligand binding assays (RBA) with patient
and control sera, and anti-NALP5 Ab. Following RBAs, immunoprecipitation of [35S]-
labelled NALP5 protein was analysed by SDS-PAGE in 8% (w/v) polyacrylamide gels
followed by autoradiography.
Antibody levels were expressed as an NALP5 antibody index. This was calculated for each
serum tested as: cpm immunoprecipitated by tested serum/mean cpm immunoprecipitated by
the population of healthy control sera. Each serum was tested in at least 2 experiments and the
mean NALP5 antibody index was calculated. The upper limit of normal for the NALP5 RBA
was  calculated  using  the  mean  NALP5  antibody  index  +  3SD  of  a  population  of  healthy
controls.  Any serum sample  with  a  NALP5 antibody index  above  the  upper  limit  of  normal
was designated as NALP5 antibody-positive.
8.4 Other antibodies (Original study IV)
We investigated the occurrence of antinuclear Abs (AN-Abs) and Abs against extractable
nuclear antigens (ENA-Abs), citrullinated peptide, and transglutaminase in 24 patients and
against bullous pemphigoid antigen 180 and desmogleins 1 (Dsg1) and Dsg3 in 30 patients of
a Finnish cohort of APECED patients. These immunological assays were performed at the
accredited Helsinki University Central Hospital laboratory, HUSLAB. Sera from 8 healthy
blood  donors  were  used  as  controls  for  each  autoantigen,  although  the  reference  values  of
HUSLAB (http://www.huslab.fi), the largest university hospital laboratory in Finland, are
based on the values in a large normal population as indicated in the accreditation documents
of the laboratory (www.finas.fi).
8.5 ELISPOT assay against AADC (Original study I)
The lymphocyte reactivity against AADC antigen was assessed in 14 patients. Precoated
plates with anti-IFNγ mAb (ELISpotPro for Human IFN-gamma, Mabtech, Nacka Strand,
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Sweden) were used to detect antigen-specific T cells secreting IFNγ in response. After
blocking of the plates as instructed, 1 µg/ml of recombinant human AADC protein (PAT-
80291-1, Nordic BioSite, Helsinki, Finland) was added, followed by the patient cells.  Frozen
and thawed PBMCs of the 14 patients were allowed to rest for 24 hr after thawing and seeded
in 300,000 cells per well in 100 μl total volume of serum-free culture medium (RPMI
Medium  1640,  Gibco,  Grand  Island,  NY,  USA).  Polyclonal  T  cell  stimulation  with  CD3-2
mAb (Mabtech) served as a positive control. After 48 hr of culture, the cells were discarded
and IFNγ secretion visualised according to the manufacturer’s instructions with BCPI/NBT-
plus (Mabtech). The coloured spots were counted using an Immunospot Analyser and the
means of triplicate wells were calculated. The cut-off for a positive response was set at 2SD
above the average basal reactivity (i.e. reactivity w/o antigen), as previously described in
similar experiments.
9 Statistical analysis
Statistical analyses were carried out using several software packages: SPSS statistics 18.0
(SPSS Inc., an IBM company); NCSS 2007 (QoL) and GraphPad Instat 3 software (GraphPad
Softwre, La Jolla, Ca). Patient characteristics and quantitative data in general were expressed
as mean (range) values and SD for continuous variables and frequencies and proportions for
categorical variables. Comparisons of categorical variables were performed using the c2 test.
Patient characteristics were compared using Fisher’s exact test for categorical variables and
the Mann-Whitney U-Test for continuous ones. Spearman’s rank correlation coefficient was
applied for continuous variables. The Pearson correlation coefficient was a measure of the
correlation between variables. The statistical significance threshold was set at P < 0.05.
10 Ethical considerations (Original studies I-VI)
The studies were approved by the Medicine Ethical Review Board of Helsinki and Uusimaa
Joint Authority (dnro 8/13/03/01/2009 for studies I to VI and dnro 276/13/03/01/2012 for
study VI) and the principles of the Helsinki Declaration were followed in collecting the
samples.   Written informed consent was obtained from the patients or,  for patients under 18
years, from the parents of the subjects.
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RESULTS AND DISCUSSION
1. Clinical component of APECED and other autoimmune diseases in the
studied cohorts
1.1. APECED (Original studies I to V)
The number of patients ranged from 26 (Original study V) to 44 (Original study III),
depending on the study (Table 6).
Among  the  34  APECED  respondents,  12  were  male  (35%)  and  22  were  female  (65%).  All
were unrelated except for 2 young girls who were sisters. The mean age was 36.9 yrs ± SD
15.0 (range 7-65). APECED had manifested in early infancy or childhood (4.0 ± 3.4 yrs) and
had evolved for 32.9 ± 13.9 yrs. The main clinical manifestations of the interviewed APECED
cohort (Rönn 2014, unpublished observations) are summarised in Table 8.
Sixty-five percent (22/34) had a complete ‘triad’ (CMC+AD+HP), while 29% (10/34)
displayed only 2 components as follows: 15% (5/34) CMC+HP, 15% (5/34) CMC+AD, and
2.9% (1/34) AD+HP (Rönn 2014, unpublished observations). Only one patient (2.9%) had
only CMC as a symptom (Figure 10).
Figure 10. Prevalence of the main components of APECED in 34 Finnish patients (Rönn
2014, unpublished observations)
CMC+AD+HP
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CMC+HP
15%
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3%
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Table 8. Prevalence of the main components of Finnish APECED patients according to Rönn
(n = 34) (Rönn 2014, unpublished observations)
Yrs: years
More than half of the patients, 56% (19/34), had 6 or more components while 44% (15/34)
had  5  or  fewer.  The  patients  had  overall  3  to  10  components  (Figure 11). On average, a
patient had a mean number of 6.3 components of APECED (Rönn 2014, unpublished
observations).
Total Men Women
n (%) 34 12 (35%) 22 (65%)
Age (y) 37 (7 – 65) 38 ± 13 (16 – 65) 36 ± 16 (7 – 57)
Age at the beginning of
APECED (yrs)
4 ± 3 (1 – 18) 4,4 ± 5 (1 – 18) 4 ± 3 (1 – 10)
Duration of APECED (yrs) 33 ± 14 (5 – 53) 33 ± 10 (14 – 47) 33 ± 16 (5 – 53)
BMI 23 ± 5 (16 - 37) 24 ± 5 (16 - 34) 22,7 ± 4 (18 - 37)
Addison’s disease 82% (28/34) 92% (11/12) 77% (17/22)
Hypoparathyroidism 82% (28/34) 58% (7/12) 95% (21/22)
Mucosal candidiasis 97% (33/34) 100% (12/12) 95% (21/22)
Hypothyroidism 29% (10/34) 17% (2/12) 36% (8/22)
IDDM 15% (5/34) 25% (3/12) 9% (2/22)
Eye manifestations 76% (26/34) 75% (9/12) 77% (17/22)
Vitiligo 24% (8/34) 42% (5/12) 14% (3/22)
Alopecia areata 50% (17/34) 83% (10/12) 32% (7/22)
Pernicious anaemia 9% 0/12 14% (3/22)
Autoimmune hepatitis 12% (4/34) 25% (3/12) 5% (1/22)
Asplenia 26% (9/34) 17% (2/12) 32% (7/22)
Ovarian insufficiency 64% (14/22)
Testicular insufficiency 17% (2/12)
Hypogonadism 47% (16/34)
Growth hormone deficiency 12% (6/34) 25% (3/12) 5%  (1/22)
Malabsorption 9% (3/34) 25% (3/12) 0/22
GI-dysfunction 56% (19/34) 50% (6/12) 59% (13/22)
Tubulointerstitial nephritis 9% (3/34) 0/12 14% (3/22)
Oral cancer 3% (1/34) 0/12 5% (1/22)
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None of the patients had a history of autoimmune connective tissue disease, rheumatoid
arthritis, celiac disease, or autoimmune cutaneous bullous disorders (Original study IV). It is
rather interesting to note that despite a lack in the negative selection of autoreactive clones,
APECED patients develop only a certain number of autoimmune diseases. For instance,
‘common’ autoimmune diseases have not been reported, such as multiple sclerosis, bullous
disorders, autoimmune thrombocytopenia or neutropenia, or Goodpasture syndrome. Cases of
celiac disease, haemolytic anaemia, and Sjögren’s syndrome are rather anecdotal (Betterle et
al 1998, Betterle et al 2003, Perheentupa 2006), raising the question of whether these
associations are fortuitous or not.
None of our patients had systemic lupus or rheumatoid arthritis (Original study IV). There are
several explanations for such discrepancies: i) the rarity of APECED makes it difficult to
detect unusual autoimmune manifestations, ii) premature deaths of patients make it difficult to
detect a disease like bullous pemphigoid that affects the elderly, iii) autoreactive T cell clones
for ubiquitous molecules may be deleted at an early stage of development, thereby preceding
AIRE-regulated events in the thymic medulla, iv) other factors may be involved, such as HLA
alleles, and v) paradoxically, by their neutralising effect, anticytokine (anti-IFN, IL-17 or IL-
22) Abs may have a protective action against the development of some autoimmune diseases.
It is interesting to note that thymoma, an uncommon tumour derived from the thymic
epithelium, which is also characterised by a lack of or diminished expression of AIRE in the
thymic tissue (Scarpino et al 2007, Liu et al 2014), is associated with a high frequency of
autoimmune diseases (Holbro et al 2012). However, these autoimmune manifestations are
quite different from those seen in APECED, mainly myasthenia gravis. For instance, cases of
pemphigus-associated thymoma have been reported (Shelly et al 2011), but not in APECED
thus far (Original study IV).
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Figure 11. Distribution of the number of components in the APECED patients (Rönn 2014,
unpublished observations)
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1.2. Addison’s disease and APS-2 (Original study VI)
Among the 107 respondents of study VI, 84 were women (78.5%) and 23 were men (21.5%)
with a mean age of 49.8 yrs. Sixty percent (64/107) fulfilled the criteria of APS-2. The
number of autoimmune components in APS-2 patients ranged from 2 to 5 (Figure 12). There
was no difference between the AD and APS-2 groups regarding age, age at diagnosis,
duration of the disease or hormonal treatments. However, a significant female predominance
was observed in the APS-2 group.
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Figure 12. Autoimmune diseases among the Finnish Addison’s disease cohort
2. Clinical manifestations (Original studies I, II and IV)
2.1. Gastrointestinal symptoms (Original study I)
2.1.1. Familial history
Regarding past family history of GI conditions, 3 unrelated patients acknowledged GI cancers
among their relatives: gastric carcinoma (n = 1) and colonic carcinoma (n = 1) in first-degree
relatives and gastric carcinoma (n = 1) in a second-degree relative. None of these relatives
was known to have a diagnosis or symptoms evocative of APECED. Lactose intolerance was
present in the families of 2/3 of the patients (63%,19/30) and celiac disease in 4 families (13%,
4/30) (Original study I).
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2.1.2. Upper gastrointestinal symptoms
GI symptoms were overall very frequent in our cohort (Figure 13).  The  most  commonly
reported upper GI tract symptoms included occasional dysphagia to solid food in 45% (14/31)
of the APECED patients. Dysphagia was associated with concomitant oropharyngeal Candida
infections only in 3 patients (Figure 14). In addition, 3 patients had a stricture/stenosis of the
oesophagus diagnosed by fibroscopy. Episodes of retrosternal chest and abdominal pain or
discomfort were present in 45% (14/31). Most of the patients reported symptoms on a
monthly  basis.  Also,  3  children  complained  of  epigastric/lower  stomach  pain  episodes.  The
parents did not link the pain episodes to any specific activity or other symptoms.
Occasional odynophagia, described as difficulties or pain when swallowing, was present in
35% of the cases (11/31). These symptoms were associated with oral and pharyngeal
candidiasis in only 3 patients (27%, 3/11). Subjective symptoms of xerostomia, i.e. a repeated
or daily feeling of dry mouth, were present in 29% of the study population (9/31). Two
patients stressed that the symptoms fluctuated according to an active Candida infection.
Although no accessory salivary gland biopsies were made, primary Sjögren’s syndrome did
not explain these symptoms since none of the patients displayed autoantibodies against
nuclear or extractable nuclear antigens, including anti-SSa/Ro and anti-SSb/La (Original
study IV). Pyrosis, defined as chest burn and the sensation of gastric acid regurgitation, was
present in 26% of the cases (8/31). One patient reported regular vomiting, about once a month,
and  one  child  on  a  regular  basis,  albeit  rarely.  Lastly,  8  patients  (26%,  8/31)  complained  of
both swallowing difficulties and dysphagia (Original study I).
A rather low percentage of patients linked the symptoms to candidiasis. In Finland, mucous
candidiasis affects almost all APECED patients (Ahonen et al 1990). According to the
literature,  15  to  22%  of  the  APECED  patients  present  with Candida oesophagitis
(Perheentupa 2006, Collins et al 2006). Thus, the upper GI tract symptoms may reflect oral
and oesophageal candidiasis, but due to the retrospective nature of our study, a recollection
bias may explain the discrepancy. Self-treatment by antifungal therapies on the appearance of
first symptoms and the improvement of candidiasis with time can also explain our results.
Eight patients had oesophagitis confirmed by fibroscopy, but only 4 of them were found to
have  candidiasis  by  PAS  staining  (12%).  These  results  are  consistent  with  the  literature
(Perheentupa 2006).
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Figure 13. Upper gastrointestinal manifestations of Finnish APECED patients (n = 31)
(Original study I)
2.1.3. Lower gastrointestinal symptoms
Half (48%) of the patients reported constipation (Figure 14). Three patients mentioned that
they had been symptom-free since childhood or adolescence. Forty percent of them (6/15)
regularly used laxatives and 2 used natural remedies or extradietary fibres. One woman
regularly performed manual anal stimulation due to severe constipation. Less than half (45%)
had unexplained periods of diarrhoea, unrelated to any viral or bacterial gastroenteritis and
lasting longer than a couple of days. In 1/3 of them, diarrhoea has been alleviated since
childhood.   Importantly,  3  out  of  4  children  had  a  history  of  diarrhoea  and  in  2  cases,
diarrhoea had been the main symptom leading to APECED diagnosis. Three patients had
experienced diarrhoea only in childhood while one adult male patient reported diarrhoea
lasting for decades and relieved only after an increased dosage of oral corticosteroids, given
as supplementation for adrenal insufficiency.  Five of the patients with diarrhoea had
steatorrhoea compatible with exocrine pancreas deficiency and 2 of them took daily
pancrelipase. Typically, in 26% of the patients constipation and diarrhoea alternated. One
third (32%) did not present any past symptoms of constipation or diarrhoea (Original study I).
Lower GI symptoms in APECED may have 3 main causes: 1) hypoparathyroidism, 2)
infection and 3) autoimmune enteropathy. Because of the retrospective nature of our study,
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we could not assess whether episodes of diarrhoea might have been related to an episode of
hypocalcaemia  or  constipation  to  a  period  of  hypercalcaemia  or  the  intake  of  oral  calcium.
Similarly, we cannot rule that some episodes may have been related to an undiagnosed
intestinal infection (Figure 15). Antifungal medication for oral candidiasis may also heal
intestinal candidiasis. One patient had chronic giardiasis found on biopsies over 10 years and
this may explain the symptoms (Figure 16). We failed to find any significant association
between any other autoimmune features of APECED and the presence or absence of chronic
diarrhoea, constipation or the alternation of the two symptoms (Original study I).
Figure 14. Lower gastrointestinal manifestations in Finnish APECED patients (n = 31)
(Original study I)
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Figure 15. Candida infection during oesophagitis in an APECED patient (x 40).
Figure 16. Chronic giardiasis between the villi in the duodenum of an APECED patient (x 20)
2.1.4. Other gastrointestinal symptoms
Less than a third of the patients (29%, 9/31) complained of subjective symptoms associated
with consuming dairy products. However, only 3 of them tested positive for lactose deficiency.
A low-lactose or lactose-free diet did not lead to symptom remission, irrespective of the
patients having been tested or not. One patient is still on a strict lactose-free diet but continues
to have chronic diarrhoea (Original study I).
None of our patients had symptoms suggestive of gluten intolerance (Original study IV). Two
patients had B12 vitamin deficiency, possibly in the context of pernicious anaemia.
74
2.2. Nephrologic and urologic clinical manifestations (Original study II)
The main manifestations are summarized in Figure 17. Ten percent of our patients (3/30) had
tubulointerstitial nephritis (TIN), confirmed with histology and without any identified cause
other than APECED. The outcome was different for each patient: one underwent kidney
transplantation, one is under dialysis and the youngest is still under follow-up. The latter, aged
12 yrs, received immunosuppressive treatment including anti-CD20 chimeric Abs
(Rituximab) with no efficacy on the creatinine levels. Renal histology disclosed the features
of TIN with an interstitial lymphocytic infiltrate, fibrosis and tubular atrophy. The infiltrating
lymphocytes were mainly T cells (CD4 + rather than CD8+) and rarely B cells (CD20+).
Immunofluorescence analysis showed deposits of IgG, C1q, C3 and kappa and lambda chains
on the tubular basement membrane (Original study II).
Figure 17. Main nephro-urologic manifestations in 30 Finnish APECED patients (Original
study II)
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3. Tissue immunohistochemistry and indirect immunofluorescence
3.1. Gastrointestinal tract (Original study I)
As reported previously, we found a decrease or a complete lack of enteroendocrine cells
(EECs) in the GI tract in 50 to 77% of the intestinal samples based on immunostaining for
chromogranin A and serotonin, respectively (Table 9, Figure 18).  The  EECs are  present  in
most of the digestive tract. They are not regrouped in clusters, but are instead distributed
singly throughout the GI tract and resemble the neurosecretory cells of the central nervous
system. They produce gastrointestinal hormones (secretin, gastrin, and cholecystokinin),
somatostatin,  and  neurotransmitters.  We  found  that  the  lack  of  serotonin  expression  was
significantly associated with the complaint of constipation (p = 0.035) (original publication I).
We also observed the lack of expression of human beta defensin 5 (hD5), secreted by PCs in
the GI crypts in 20% of our samples, possibly indicating the lack of PCs here (Original study
I).
Table 9. CgA- and 5-TH positive cells in the intestinal tract of APECED patients who
underwent endoscopic investigations
Chromogranin A-
positive/crypt
Serotonin-positive
cells/crypt
Total patients 10 9
Biopsies 16 14
Duodenal positivity 50% (5/10) 22% (2/9)
Ileal positivity 0% (0/1) 0% (0/1)
Colon and rectal
positivity
0% (0/3) 0% (0/3) and 0% (0/2)
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Figure 18. Chromogranin A staining in a normal duodenojejunum (left) and absence of
staining in an APECED patient (right)
Lastly, we performed staining of villin, a 92.5kDa actin-binding cytoskeletal protein which
associates with the apex and axial bundle structures of intestinal microvilli to mediate
cytoskeletal organisation in the intestine. Several teams recently showed that villin is a
potential target of Abs in IPEX patients (Kobayashi et al 2011, Lampasona et al 2013). As
IPEX exposes to a paediatric form of autoimmune enteropathy, we investigated the possibility
that villin is a possible target of autoimmunity in APECED. Compared with normal intestinal
tissue (strong staining in the brush borders and cytoplasm, it disclosed fainter staining but also
a wide range of reactivity patterns (apical expression, basal). However, we could not
determine a specific pattern or the relevance of this abnormal expression in the gut (Original
study I).
IL-17 is a key cytokine in the control of the gut microbiotia (Blaschitz et al 2010, Rubino et al
2012). As APECED patients display circulating antibodies against IL-17, we hypothesised
that IL-17 expression would be impaired in the intestinal samples of our patients. Thirteen
samples, mainly for the duodenum, from 9 patients were stained for IL-17 expression. We
observed that 77% of our samples showed a decrease or lack of expression of IL-17 (Figure
19). However, we could not confirm the relationship between symptoms and lack of IL-17 in
the samples (Original study I).
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Figure  19.  IL-17  staining  in  a  normal  colon  (left)  and  absence  of  staining  in  an  APECED
patient (right)
Indirect immunofluorescence (IIF) of normal duodenum and ileum with the sera of 29 patients
revealed strong staining directed against cellular parts of  PCs (20%, 6/29) and enterocyte
brush borders (24%, 7/29) in the APECED patients (Figure 20). The sera of 15 healthy blood
donors were negative for staining. The implication of such Abs against PCs is not yet clear as
we failed to find a direct correlation between the lack of hBD5 expression and GI symptoms
(Original study I). Interestingly though, one of our patients with strong IIF positivity against
duodenal and ileal PCs had no duodenal hBD5 positivity.
Figure 20. Strong staining in the crypt of the duodenum with positive staining of the
Paneth cells
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3.2. Kidney (Original study II)
When we stained rat kidney sections with the sera of our patients, we observed in 30% of the
sera (9/30) restricted positive immunostaining in the distal part of the nephron, consisting of
the distal tubules, Henle’s loop and collecting tubules. The intensity varied among the
patients, but no staining was seen in other renal structures, including the proximal tubular
epithelium. All 3 patients with TIN disclosed this pattern (Figure 21). The sera of 15 healthy
blood donors were all negative. There was consistent negative staining of rat spleen sections,
which were used as a control tissue, for both patient and healthy blood donor sera (Original
study II).
Figure  21.  Orange  staining  of  the  distal  part  of  the  tubules  with  the  serum  of  a  young
APECED patient with TIN (x 4)
3.3. Palpebra (unpublished data)
The  question  remains  open  as  to  whether  the  meibomian  glands  are  affected.  Indeed,  a
meibomian gland dysfunction causes symptoms that mimic keratitis, with eye itching, eye
burning, puffy eyes, dryness, watery tears, crusty lashes, and ocular redness. We noted in sera
from 28 patients that half of them (14/28, 50%) specifically stained the meibomian glands of
palpebral rat section (Kluger N et al, data unpublished, Figure 22). None of the controls
stained any structure of the palpebral rat sections.
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Figure 22. Positive staining of meibomian glands of rat eyelids with APECED serum (x 10)
(Kluger et al, unpublished data)
4. Autoantibodies and autoreactive T cells
4.1. Circulating antibodies against cytokines (Original studies I and II)
Twenty-eight sera were assessed for circulating Abs against cytokines (Figure 23). Briefly,
all  the patients had Abs against  IFN-a and IL-22 and 90% against IFN-w. When correlating
this antibody reactivity with the clinical symptoms, we found a statistical association with the
presence of constipation and IL-17F Abs. We failed to find any association with TIN.
Figure 23. Prevalence of anticytokine antibodies in 28 APECED patients (cut-off defined a
mean + 3SD of blood donors)
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4.2. Circulating antibodies against tissue antigens (Original studies I, III and IV)
As emphasised in our review of the literature, APECED patients develop circulating Abs
against  a  multitude  of  target  antigens.  Anti-TPH1 has  been  shown to  be  associated  with  GI
manifestations (Ekwall et al 1998, Scarpa et al 2013). Anti-AADC is found in APECED
(Söderbergh et al 2004) but has not been studied specifically in GI manifestations of
APECED. Because harmonin (AIE-75) and villin are targeted by antibodies in autoimmune
enteropathies (Patey-Mariaud de Serre et al 2009), especially villin in IPEX (Kobayashi et al
2011, Lampasona et al 2013), we investigated whether these Abs are found in APECED. We
also investigated Abs against gastrin, a neurohormone that stimulates the secretion of gastric
acid by the parietal cells of the stomach and helps in gastric motility. It is released by G
cells in the pyloric antrum of the stomach, but also duodenum, and the pancreas (Figure 24).
In our series, 51 and 39% of the patients had anti-AADC and anti-TPH1 Abs (Original study
I).  The  results  are  quite  close  to  the  prevalence  found  by  Söderberg  et  al  (Söderbergh  et  al
2004) and Husebye et al (1997). As a novel finding, we found a statistical association between
anti-AADC  positivity  and  constipation  and  anti-TPH1  and  GID.  We  also  observed  a
cumulative  effect  as  patients  with  both  Abs  had  more  constipation  and  GID  than  those
without these Abs (Original study I).
In addition, we observed that 1/3 of our patients had Abs against harmonin (AIE-75), an
antigen of interest involved in autoimmune enteropathy (Patey-Mariaud de Serre et al 2009),
and also villin, which has recently been named as a possible target in IPEX patients
(Kobayashi et al 2011, Lampasona et al 2013). However, there was no statistical link between
these Abs and the clinical symptoms.
The question of whether these Abs (AADC, TPH-1, AIE-75, villin) are directly involved in
the physiopathogeny of GID remains unanswered. We cannot rule out that these Abs appear
secondarily as a consequence of the immune aggression or simply reflect the thymic inability
to negatively select autoreactive clones (Original study I).
On the other hand, we found no transglutaminase (for celiac disease, 0/24) or anti-desmoglein
1 (pemghigus foliaceus, 0/30) antibodies in our cohort of patients.  Two patients disclosed
positivity for anti-BP180 (bullous pemphigoid) with no clinical symptoms. Anti-desmoglein 3
was also positive at a low level in 2 patients without clinical symptoms. Lastly, 25% of our
patients had antinuclear Abs at 1:80, a level not considered clinically significant (6/24) and
none had anti-citrullinated peptide antibodies (Original study IV).
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Figure 24. Prevalence of antibodies against gut antigens in 31 APECED patients (cut-off
defined as mean + 3SD of healthy blood donors).
Thirty-six percent of the patients (16/44) and none in the healthy control group had CaSR Abs
(p < 0.0001), while NALP5 Abs were found in 30% of the patients and in none in the control
group (13/44,  p <0.0001). However, we found no statistical association between these Abs
and the clinical manifestations, including HP, nor was there any gender prevalence among
those with Abs. Only an association between a shorter duration of evolution of HP (less than
10 y) and CaSR positivity was found (Original study III).
4.3. AADC-specific T cell response (Original study I)
To better understand the background of the AADC-specific Abs, we studied 14 patients.
Forty-three  percent  (6/14)  of  our  patients  and  no  healthy  controls  had  a  positive  T  cell
response against AADC (Figure 25). However, no association was found between the T cell
response,  the presence or absence of AADC Abs, constipation and GID in this small  patient
sample (Table 10).
Table 10. T cell response, clinical symptoms and AADC-antibodies in 14 APECED patients
ELISPOT + (6) ELISPOT – (8) p < 0.05
GID + 50% (3) 62% (5) NS
GID - 50% (3) 37.5% (3)
Constipation + 50% (3) 37.5% (3) NS
Constipation - 50% (3) 62% (5)
AADC-Abs + 66% (4) 62% (5) NS
AADC-Abs  - 33% (2) 37.5% (3)
NS: Not significant
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Figure 25. Example of the detection of an AADC-T cell response by ELISPOT: APECED
patient with no IFN-g production upon T cell stimulation (left) and APECED patient with a
positive response and production of IFN-g (right)
5. Nonendocrine tissue-specific antibodies: simple reflections or active actors
in autoimmunity in APECED?
In our studies, we observed that APECED patients had circulating Abs against various
intestinal  targets  such  as  TPH-1,  AADC,  AIE-75,  villin  and  Paneth  cells  (Original  study  I)
and against renal tubular proximal cells (Original study II), and we confirmed the immunity
against  parathyroid  antigens  (Original  study  III).  However,  we  failed  to  show  a  statistically
significant association between circulating Abs and the symptoms of clinical failure of the
involved organ, sometimes even with results that conflicted with the findings of previous
studies published in the literature. There are several explanations for these discrepancies.
5.1. Origin of the patients and data collection
Our cohort includes only Finnish patients. In a high number of published series on Ab assays,
the  population  has  often  been  heterogeneous.  Even  when  all  patients  are  from  Northern
Europe, discrepancies are noted. For instance, a considerable variation in the prevalence of
TPH-1 Abs in Swedish (100% of positivity), Finnish (37%) and Norwegian (22%) patients
(Ekwall  et  al  1998)  has  been  reported.  Also,  although  an  association  between  TPH-1  and
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gastrointestinal dysfunction was found in Scandinavian patients, it was not found in an Italian
series (Dal Pra et al 2004).
The size of the cohort may play a role in determining the prevalence of circulating Abs, and
the variability in the assay methods is discussed below (6.2). Some manifestations are, by
definition,  so  frequent  in  APECED,  like  HP,  that  the  number  of  APECED  patients without
such a manifestation is too low for a significant result in a comparative study (Original study
III).
An important aspect – too often neglected in our opinion – regarding GI manifestations is the
lack of specificity about the reported symptoms. The studies are unclear regarding patient GI
symptoms. For example, considerable confusion surrounds the definition of GI ‘dysfunction’:
for some it is ‘steatorrhoea, watery diarrhoea, or constipation’ (Ekwall et al 1998) and for
others it is only ‘malabsorption’ (Dal Pra et al 2004, Bratland et al 2013).
For this reason, we preferred to separate (chronic) ‘diarrhoea’ from (chronic) ‘constipation’ or
the alternation of the two. Besides, malabsorption has a very specific definition, mainly based
on confirmed steatorrhoea (Kluger et al 2013). As stressed in the discussion, both
hypocalcaemia and infections can cause diarrhoea. Thus, confounding factors may explain the
discrepancies among studies. Lastly, as stressed by all the studies, patients with no symptoms
may also have Abs. Due to the retrospective nature of our studies, based mainly on self-
reported symptoms, we cannot totally rule out a potential bias of recollection or
misinterpretation of some of the symptoms.
5.2. Antibody detection methods
An important factor that may explain the discrepancies among studies is the method used. We
used mainly ELISA assays with a cut-off of 3SD above the mean based on healthy blood
donor results. However, other tests like the radioenzymatic assay using full-length or
modified radiolabelled antigens have been used in other publications (Ekwall et al 1998, Dal
Pra  et  al  2004),  so  the  outcomes  are  not  completely  comparable.  Interestingly,  Dal  Pra  et  al
(2004) observed that Abs against AADC and TPH1 interacted with different epitopes and that
different sera had different inhibiting effects, suggesting the heterogeneity of Ab binding sites.
The potential in vivo implications are not clear but they may explain the discrepancies
between studies about a given symptom and the presence or absence of an Ab of interest.
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5.3. The role of the targets
Self-antigens are classified as the following: 1) self-antigens expressed constitutively in all
cell  types,  2)  self-antigens  of  restricted  tissue  expression  but  present  in  the  circulation  at
various levels, 3) self-antigens of restricted tissue expression that are undetectable in the
circulation, and iv) sequestered antigens (Sospedra at al 2008). If the target of the Ab is
expressed on the cell surface, the Abs may have a direct functional action through
complement fixation or Ab-dependent cytotoxicity. Abs may also have antagonist or agonist
activity when binding to the target. If the tissue antigen is intracellular (like intracellular
enzymes), a direct effect of Abs is seen as rather improbable (Artstila et al 2013) and in this
case the Ab would just be a stigma of the autoimmunity against the organs. With time, as the
targeted organ is destroyed, the lack of immune stimulation may result in the disappearance of
the Abs.
Lastly, the detected Abs could simply be an epiphenomenon, a reflection of the defect in
deleting auto-reactive clones in the thymus and the periphery, leading to the production of a
multitude of Abs with limited biological activity (Figure 26).
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Figure 26. The genesis of anti-tissue antibodies:  pathogenic or simple witnesses of
autoimmunity in APECED. Abs are produced after exposure to antigens that are released
after cytotoxic aggression by T CD8 cells and a lack of T reg regulation. Abs are detected by
various  assays  and  may  be  a  useful  tool  to  diagnose  a  disease  if  their  sensitivity  and
specificity are high enough (at best 100%). Hypotheses of their pathogenicity include
complement-dependent cytoxocity (1) and/or immune complex deposits (2). Abs may cross-
react with other antigens (3), without certainty that such cross-reaction would be
pathogenic.
6. What is the role of autoimmunity in the lower gastrointestinal manifestations
of APECED?
6.1. Autoimmune enteropathy in APECED
As previously pointed out in the literature review section (Kluger et al 2013), there are three
main groups of causes that can lead to lower GI symptoms: chronic infection, metabolic
disorders, mainly hypocalcaemia, and autoimmune enteropathy. There are also other rarer
causes, not discussed herein. In addition, various causes may be simultaneously combined or
may explain different episodes in the patient. Hypocalcaemia and infection(s) should be
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systematically  ruled  out  in  cases  of  chronic  diarrhoea.  Autoimmune  enteropathy  remains  a
diagnosis of exclusion. Arguments that support an autoimmune enteropathy include: i) the
lack of EECs, ii) the existence of Abs against cellular targets on IFI, iii) circulating Abs
against neurotransmitters in the gut, iv) the presence of a lymphocytic infiltration in the gut as
reported in the literature in some patients (Kluger et al 2013), and v) the need for
immunosuppressive treatment of such symptoms, even though its efficacy is variable (Ward et
al 1999, Kluger et al 2013).
The clinical relevance of the brush border staining and the circulating Abs against AIE-75 and
villin, which are established targets in IPEX, another cause of autoimmune enteropathy, is of
unclear significance in APECED.
It is clear that additional (and possibly numerous) other factors play a role in the pathogenesis
of the GI symptoms, including individual genetic and epigenetic factors, local cytokine
production, the enteric nervous system, and the enteric microbiota. We hypothesise that
immunity has a direct impact on the intestinal microbiome, which may explain the GI
manifestations in APECED patients.
6.2. Enteroendocrine cells and the gut microbiota
The local resident intestinal microbiota (gut flora) plays an essential role in mediating host
physiology, metabolism and immune response. For instance, this microbiota is essential for
regulating proper nutrient and vitamin intake, preventing colonisation by bacterial pathogens
and promoting the development of secondary lymphoid structures like Peyer’s patches and
intestinal lymphoid follicles (Rubino et al 2012).
The EECs are involved in intestinal growth, blood flow, motility, secretion of pancreatic
enzymes and bile. These cells, located throughout the intestinal tract, are accessible to enteric
microbiota on the lumen side but are also in contact with afferent and efferent nerve terminals
on the lamina propria side, which provides them contact with the central nervous system
(Rhee et al 2009). They secrete numerous peptides in response to physiological or
pathological stimuli, including serotonin (5-HT). 5-HT can be secreted on both sides of the
intestinal epithelium by the EECs, into the intestinal lumen or into the basolateral sides.
Pathogenic bacteria in the GI tract can increase 5-HT secretion in the lamina propria (Rhee et
al 2009). Similarly, the enteric microbiota can modulate intestinal motility and gut transit.
Disruption of the balance between enteric microbiota populations might induce gut motility
and secretion alterations that would in turn influence the balance of enteric microbiota (Rhee
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et al 2009). Therefore, the lack of EECs can explain severe GI manifestations. However, there
is not a strict correlation and the disappearance of EECs is not permanent, as these cells
typically have a high turnover. We observed a significant association between the lack of 5-
HT expression in the intestinal tissue and constipation. In addition, we report here a novel
association between constipation and AADC Abs, AADC being an enzyme involved in the
serotonin pathway. Therefore, a cellular immune aggression directed against EECs combined
with Abs against the 5-TH pathway may impair the secretion of 5-HT in the gut. In fact, 5-HT
levels were shown to be lower in patients with TPH-1 Abs (Scarpa et al. 2013). Different
targets on the same pathway may have cumulative effects. A dysfunction of the 5-HT
pathway in the gut may disturb the crosstalk between the microbiota, the gut and the brain,
leading to dysbiosis (Frank et al 2011, Salzman et al 2013).
6.3. The IL-17/IL-22 pathway and the gut microbiota in APECED
It is currently unknown whether IL-17- and IL-22-neutralising Abs have an influence on gut
physiology and the GI manifestations of APECED.
The microbiota is required for the generation of Th17 cells in the lamina propria. Segmented
filamentous bacteria (SFB, members of the Clostridium genus) induce a Th17 response in the
small intestine (Rubino et al 2012). Moreover, SFB also upregulate basal gut IFNg+ Th1 and
FOXP3+ regulatory T cell responses (Rubino et al 2012).
Th17 cells and the subset of cytokines they produce, such as IL-17A, IL-17F and IL-22, are
involved in the organisation of the mucosal defence against pathogens (Blaschitz et al 2010,
Rubino et al 2012). Interestingly, gd T cells, NK, NKT and dendritic cells are also involved in
the production of IL-17 and IL-22 (Blaschitz et al 2010). Thus, IL-17 and -22 prevent
infection dissemination and upregulate chemokines (CXCL-8, CCL20) and G-CSF, thereby
recruiting and activating neutrophil cellular responses at inflammation sites and antimicrobial
responses (iNos, lipocalin-2, defensins); they also reinforce tight junctions between
enterocytes and enhance cell proliferation (Blaschitz et al 2010, Rubino et al 2012). We could
not find any link between the lack of IL-17 expression in the mucosa and the presence of
clinical lower GI symptoms. However, the presence of IL-17 Abs, which are known to have
neutralising activity, and the diminished expression of IL-17 in the small intestine of some of
our patients are strong indications of an impact on the gut flora. For instance, chronic
intestinal  giardiasis  has  been  reported  in  APECED patients  and  was  observed  in  one  of  our
patients (Kluger et al 2013). It was recently shown that IL-17 production is important in the
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clearance  of  a Giardia muris infection with early induction of peroxisome proliferator-
activated receptor alpha (Dreesenet al 2014). Thus, the IL-17 pathway may favour not only
CMC in APECED but also the occurrence of intestinal infections (bacteria, candidiasis or
parasitic infections).
6.4. Paneth cells and the gut microbiota in APECED
Paneth cells are located at the base of the small intestinal crypts of Lieberkühn, interspersed
with epithelial stem cells at this location. They have an intensive secretory activity for a wide
variety of peptides, the most abundant being the antimicrobial peptides (Salzman et al 2013),
especially a-defensins, but also lectins, lysozyme and secretory phospholipase A2, which
contribute to mucosal host defence. They regulate the composition of the intestinal bacterial
microbiome (Salzman et al 2010) and they protect from pathogenic microbes (Salzman et al
2013). Mouse models overexpressing hD5 show a significant loss of segmented filamentous
bacteria (SFB), resulting in reduced numbers of Th17 cells in the lamina propria. PC
defensins may thus regulate the small intestinal microbiome (Salzman et al 2010). They are
also involved in maintaining the growth and survival of crypt stem cells (Salzman et al 2013).
There are various genetic and environmental factors that can induce PC dysfunction (Salzman
et al 2013), but direct immunity as a cause of PC depletion has not been reported, to our
knowledge.
The  role  of  the  circulating  Abs  against  PCs  remains  to  be  defined  in  APECED,  but  a
pathophysiological role is possible. The precise target is not known; although the
immunostaining we observed was located in the granules, it could be directed to one of the
antimicrobial peptides. As some of our patients had clearly specific Abs against granules and
we observed the lack of hD5 expression in 20% of our cases, defensins could be a possible
target of autoimmunity in APECED.
However, as stressed by Salzman et al, it is not always clear whether modification of the
microbiota is a cause or the consequence of PC dysfunction (Salzman et al 2013) (Figure 27).
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Figure 27. The role of innate IL-17 and IL-22 responses to enteric bacterial infections and
the endocrine cell-mediated signalling in the enteric microbiota-host interaction (adapted
from Rubino et al 2012 & Rhee et al 2009). Dendritic cells (DC) are activated by pathogens
and secrete several cytokines that stimulate different subsets of T cells (Th17 cells, gd T cells,
NK and NKT cells) to secrete IL-17 and IL-22.  IL-17 promotes amplification of the host
response by recruiting neutrophils, while IL-22 promotes barrier functions by enhancing
production of antimicrobial peptides from Paneth cells. The Th17 response prevents
bacterial dissemination from the gut and promotes colonisation of the mucosa by pathogens
resistant to some of the antimicrobials.
Furthermore, EECs can secrete 5-HT on either side of the intestinal epithelium either under
the influence of the microbiota or under the action of afferent neurons in response to the
content of the digestive tract.
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6.5. From autoimmunity to disturbance of the gut microbiota (dysbiosis) in
APECED
Based on all these data, we hypothesised that constipation is most likely related to EEC
deficiency/dysfunction of the serotonin pathway in the gut through autoimmune aggression.
The Abs against AADC (and TPH1) could promote symptoms of constipation by blocking the
serotonin metabolism. Conversely, isolated chronic diarrhoea may have additional causes
(hypocalcaemia, candidiasis, infections, malabsorption) (Kluger et al 2013) or the calcium
supplementation itself is responsible for constipation. Of course, other Abs and pathways may
play additional roles, such as histidine decarboxylase as reported previously.
Furthermore, the Abs against PCs combined with those against the IL-17/IL-22 pathway may
modify the local microbiota. They may facilitate the growth of infectious agents such as
Candida albicans or Giardia lamblia and lead to symptoms, adding on possible other causes
such as hypocalcaemia or pancreatic exocrine failure.
According to the models of dysbiosis (the modification of microbiota to an unfavourably
skewed one) as highlighted by Frank et al (Frank et al 2011), we think that the GI
manifestations in APECED fit  best  with the following pathway: the dysbiosis arises because
of the pathological condition itself (autoimmunity) and the change in composition of
microbiota may further contribute to disease severity and/or duration (Figure 28). Therefore,
future prospective studies on the intestinal microbiota of patients with newly diagnosed
APECED are warranted.
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Figure 28. Significance of dysbiosis. Dysbiosis is a primary factor causing disease
pathogenesis (a), dysbiosis has no aetiological consequences on the disease but is the result
of aetiological agents (b), dysbiosis is the result of the disease itself (c), and the change in
composition in microbiota might contribute to disease severity, duration or frequency (d). In
the case of GI manifestations in APECED, we speculate that the path is (c)/(d) (adapted from
Frank et al (Frank et al 2011)).
7.  The  quality  of  life  of  APECED  patients  and  AD/APS-2  patients  (Original
studies V and VI)
Twenty-six patients with APECED took part in our study on HRQoL (Original publication V).
Briefly, we found that general health perceptions and energy/fatigue/vitality were the most
affected items in the SF-36 questionnaire (Figure 29). Male patients also seemed more
affected than women, even though the difference was not significant. We could not find any
correlation between the outcomes of the SF-36 items and the number of clinical components
that the patient had. We also used a specific depression-related questionnaire (RBDI) to detect
whether these patients had depressive symptoms. One third (30%) of the patients had mild to
severe depressive symptoms, but only 7.7% had moderate to severe depressive symptoms. Six
patients had mild symptoms, while 2 patients, under antidepressive treatment, still had
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moderate to severe depressive symptoms. Two additional patients were under antidepressive
therapy with good efficacy as they both scored 0. Fatigue, well-being, and general health were
negatively correlated with the RBDI score. In other terms, depressive symptoms were
associated with increased fatigue and decreased well-being and general health perceptions.
Lastly, we investigated whether visible skin manifestations such as vitiligo, candidiasis or AA
had an impact on QoL using a specific questionnaire related to skin disease, the DLQI.
Overall,  the  impact  of  skin  disease  was  rather  low.  Not  surprisingly,  women  with  AA
universalis reported the highest scores of impairment, even though these scores indicated only
a ‘moderate’ effect on QoL. Before our study, only Løvås et  al  had  assessed  the  HRQoL of
APECED patients but in a smaller series (Løvås et al 2002), and our results are close to their
observations.   We found some interesting  results  in  our  studies  despite  the  small  number  of
patients, the obvious design limitations with the small sample size, the lack of an age-, sex-
and dispersed geography-matched Finnish healthy control group, and the absence of data
regarding other potentially confounding factors like socioeconomic features. One of these was
that HRQoL was not as impaired as one might have anticipated. The accumulation of disease
components did not have an impact on HRQoL. The male patients appeared to be more fragile,
although the difference was not significant. We also concluded that the older the patients were,
the better they coped, as illustrated by a negative correlation between a low total RBDI score,
elevated age and long duration of this disease.  Such results may be explained mainly by the
fact that we interviewed a cohort of patients who have lived a long time with the disease (e.g.
35 yrs) and have learned to cope with it. Besides, disabling symptoms like CMC improve
with time and patients are used to adapting self-medication at the first sign of symptoms. The
beneficial effect of the patients’ association is also possible, as most of the patients were
members. The low number of patients may help ensure the quality of peer support.
Nevertheless, our results cannot be applied to an individual level, and clearly some patients
suffered more from the disease at certain points in their lives due to the accumulation of
components or because of specific disabilities (Figure 30). We also observed that young
patients seemed to be more sensitive to an impairment in QoL.
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Figure 29. SF-36 quality of life outcomes for the Finnish APECED patients
Figure 30. The overall burden of APECED
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One year later, we performed a similar study of HRQoL among Finnish patients with AD
and/or APS2 (Original study VI). For this study, we used 2 HRQoL scales: the 15D (Figure
31) and the SF-36 (Figure 32).  This  15D score  study  is  much stronger  as  we  compared  the
data with an age- and gender- standardised population. There was a significant impairment of
the 15D score in the patient group compared with the controls (0.853 vs 0.918, p < 0.001).
The impairment in HRQoL was related to patients’ association membership, female gender,
lower education, other autoimmune or inflammatory disorders that were not part of APS-2,
and longer disease duration. Interestingly though, having APS-2 (as opposed to only AD) did
not lead to any significant difference, nor did the number of autoimmune components of APS-
2, again indicating that this criterion was not decisive in our Finnish cohort. Another very
positive aspect was that the Finnish AD patients were treated according to the current
hydrocortisone substitution recommendations (a hydrocortisone dose of 20 mg/d). As we did
not perform a comparative study with a normal population using the SF-36 in either study, we
cannot draw direct comparisons between these two. There are numerous factors that might
have interfered, such as the age of the cohort and also the delay in disease progression, as
typically AD/APS2 is diagnosed during adulthood.
We also wondered about the possible impact of belonging to the patients’ association, since
we observed in the second study that belonging to the patient’s association was associated
with lower HRQoL. We speculate a possible deleterious impact of membership on the QoL
for patients with only AD/APS2 because they belong to an association guided by patients with
APS1. Despite a similarity in the name, APS1 and APS2 are quite different diseases. Mixing
patients with different diseases under the same association may have an impact on HRQoL.
The  patients’  expectations  may be  different  in  terms  of  information  to  patients,  topics  dealt
with in patient meetings and overall patient objectives.
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Figure 31. 15D score outcomes for the Finnish AD patients and the control group
Figure 32. SF-36 quality of life outcomes for the Finnish AD and APS-2 patients
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CONCLUDING REMARKS AND FUTURE DIRECTIONS
Despite the clear monogenic background, the pathogenesis of human APECED remains
unresolved. The reasons why patients present such a diversity of manifestations is unclear.
Our study showed that gastrointestinal manifestations were frequent when patients were
specifically asked to report them. Patients develop Abs against various antigens (TPH-1,
AADC, AIE-75, etc.) in the gut, mainly neuro-endocrine targets. The pathogenic relevance of
such Abs is nevertheless not that clear. The GI manifestations seem to be multifactorial,
including disturbances in calcium metabolism, possible intestinal infections, and humoral and
cellular autoimmunity directed against the gut tissue. We hypothesised that all these factors
may affect the local gut microbiota of patients, leading to a vicious circle. Further studies
should focus on analysing the gut microbiota to assess whether or not it is disturbed in
APECED patients and related to their GI symptoms. Moreover, studies on Abs in APECED in
general should screen multiple Abs and try to link them to a symptom rather than just to one
autoantibody. The targets of immunity in the kidney seem to be located towards the renal
tubules, yet the antigens remain to be identified. Our study confirmed that distal tubular cells
are likely to be the target of autoimmunity during APECED. Specific immunoscreening with
serum samples from APECED patients of a human renal cDNA library should help to detect
possible molecular renal targets.
We failed  to  show that  CaSR and  NALP5 antibodies  were  specific  or  sensitive  markers  for
HP in our cohort. The precise role of the autoimmune response against CaSR and NALP5 in
the pathogenesis of APECED is still unknown. A parathyroid-specific antigen associated with
HP to allow serologic diagnosis of the disease is still missing.
The  role  of  cytokine  Abs  and  how  they  influence  autoimmune  manifestations  remain  to  be
elucidated. APECED patients seem to be protected from some of the ‘classic’ autoimmune
diseases such as systemic lupus or polyarthritis, raising questions about whether these Abs are
protective.
HRQoL is  impaired  for  some of  the  patients  with  APECED,  but  not  as  much as  one  would
have expected when looking at the accumulation of symptoms. The role of peer support via a
patients’ association may well be involved, as would better patient management in Finland
than in the past. Interestingly, the question of whether patients with AD and APS-2 should
still be affiliated with the association of APECED patients is open for debate, as patients with
AD/APS-2 have a different profile than that of APECED patients and, paradoxically, this may
impact their HRQoL.
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